{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:19:29Z","timestamp":1791994769000,"version":"4.4.0"},"reference-count":1141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["2017SNRXH3"],"award-info":[{"award-number":["2017SNRXH3"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 2017 - ID. 20353"],"award-info":[{"award-number":["IG 2017 - ID. 20353"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health","award":["RC18-2638151"],"award-info":[{"award-number":["RC18-2638151"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pharmthera.2020.107579","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T12:48:48Z","timestamp":1589892528000},"page":"107579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges"],"prefix":"10.1016","volume":"213","author":[{"given":"G.R.","family":"Tundo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sbardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Coletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Oddone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Milardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Lacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Coletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb0005","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nature Reviews. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107579_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treatment Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nature Reviews. Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb0030","first-page":"2615","article-title":"Proteasome inhibitors: A novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/0301-4738.53049","article-title":"Current concepts in the pathophysiology of glaucoma","volume":"57","author":"Agarwal","year":"2009","journal-title":"Indian Journal of Ophthalmology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","article-title":"Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia","volume":"151","author":"Agathocleous","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccr.2004.09.003","article-title":"Nuclear factor-kappaB: The enemy within","volume":"6","author":"Aggarwal","year":"2004","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bbrc.2013.01.101","article-title":"High glucose and diabetes modulate cellular proteasome function: Implications in the pathogenesis of diabetes complications","volume":"432","author":"Aghdam","year":"2013","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mcn.2013.11.001","article-title":"Proteasome inhibition induces stress kinase dependent transport deficits - implications for Alzheimer's disease","volume":"58","author":"Agholme","year":"2014","journal-title":"Molecular and Cellular Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb0060","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1074\/jbc.M114.614925","article-title":"The E3 ubiquitin ligase parkin is recruited to the 26 S proteasome via the proteasomal ubiquitin receptor Rpn13","volume":"290","author":"Aguileta","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0065","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1074\/jbc.272.3.1791","article-title":"Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum","volume":"272","author":"Akopian","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0070","doi-asserted-by":"crossref","DOI":"10.1007\/s12640-020-00185-1","article-title":"Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer's disease","author":"Al Mamun","year":"2020","journal-title":"Neurotoxicity Research. Scopus."},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0075","doi-asserted-by":"crossref","DOI":"10.4161\/mco.29906","article-title":"Noxa and cancer therapy","volume":"1","author":"Albert","year":"2014","journal-title":"Molecular & Cellular Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb0080","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0085","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/ed083p728","article-title":"The discovery and development of cisplatin","volume":"83","author":"Alderden","year":"2006","journal-title":"Journal of Chemical Education"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0090","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0095","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1196\/annals.1354.056","article-title":"Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes","volume":"1067","author":"Ali","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb0100","doi-asserted-by":"crossref","first-page":"10599","DOI":"10.1073\/pnas.92.23.10599","article-title":"Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway","volume":"92","author":"Alkalay","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","article-title":"The proteasome: A novel target for cancer chemotherapy","volume":"16","author":"Almond","year":"2002","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb0110","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nature Genetics"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb0120","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/0008-5472.CAN-04-0673","article-title":"Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma","volume":"64","author":"Amiri","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.aca.2019.09.042","article-title":"Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer's disease","volume":"1093","author":"Amor-Guti\u00e9rrez","year":"2020","journal-title":"Analytica Chimica Acta"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0130","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.leu.2401812","article-title":"Protease inhibitor-induced apoptosis: accumulation of wt p53, p21 WAF1\/CIP1 , and induction of apoptosis are independent markers of proteasome inhibition","volume":"14","author":"An","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2014.11.018","article-title":"Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways","volume":"81","author":"Anandhan","year":"2015","journal-title":"Neurobiology of Disease"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0140","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0145","doi-asserted-by":"crossref","first-page":"12896","DOI":"10.1038\/s41598-019-46237-1","article-title":"G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10","volume":"9","author":"Anisimov","year":"2019","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/jpet.115.226993","article-title":"Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines","volume":"355","author":"Ao","year":"2015","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0155","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/mp300044b","article-title":"Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib","volume":"9","author":"Ao","year":"2012","journal-title":"Molecular Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0160","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/jjco\/hyr063","article-title":"Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: A report from retrospective study","volume":"41","author":"Aoki","year":"2011","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0165","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0170","doi-asserted-by":"crossref","unstructured":"Arba, M., Nur-Hidayat, A., Ruslin, Yusuf, M., Sumarlin, Hertadi, R., Wahyudi, S. T., Surantaadmaja, S. I., & Tjahjono, D. H. (2018). Molecular modeling on porphyrin derivatives as \u03b25 subunit inhibitor of 20S proteasome. Computational Biology and Chemistry, 74, 230\u2013238. https:\/\/doi.org\/10.1016\/j.compbiolchem.2018.03.002.","DOI":"10.1016\/j.compbiolchem.2018.03.002"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb0175","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/emboj\/18.13.3575","article-title":"Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly","volume":"18","author":"Arendt","year":"1999","journal-title":"The EMBO Journal"},{"issue":"45","key":"10.1016\/j.pharmthera.2020.107579_bb0180","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1038\/onc.2009.264","article-title":"Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)","volume":"28","author":"Arlt","year":"2009","journal-title":"Oncogene"},{"issue":"34","key":"10.1016\/j.pharmthera.2020.107579_bb0185","doi-asserted-by":"crossref","first-page":"20723","DOI":"10.1016\/S0021-9258(17)45274-4","article-title":"Assembly of the 26 S complex that degrades proteins ligated to ubiquitin is accompanied by the formation of ATPase activity","volume":"265","author":"Armon","year":"1990","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1389202915666140210210542","article-title":"Interrelation between protein synthesis, proteostasis and life span","volume":"15","author":"Arnsburg","year":"2014","journal-title":"Current Genomics"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb0195","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"6152","key":"10.1016\/j.pharmthera.2020.107579_bb0200","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/331192a0","article-title":"Identity of the 19S \u201cprosome\u201d particle with the large multifunctional protease complex of mammalian cells (the proteasome)","volume":"331","author":"Arrigo","year":"1988","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0205","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.yjmcc.2008.11.001","article-title":"PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts","volume":"46","author":"Asai","year":"2009","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"6220","key":"10.1016\/j.pharmthera.2020.107579_bb0210","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.1261197","article-title":"Proteasomes. A molecular census of 26S proteasomes in intact neurons","volume":"347","author":"Asano","year":"2015","journal-title":"Science (New York, N.Y.)"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0215","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0220","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gad.319905","article-title":"A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73","volume":"19","author":"Asher","year":"2005","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0230","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/stem.1113","article-title":"A putative role for the immunoproteasome in the maintenance of pluripotency in human embryonic stem cells","volume":"30","author":"Atkinson","year":"2012","journal-title":"Stem Cells (Dayton, Ohio)"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb0235","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cell.2011.03.036","article-title":"Single-molecule protein unfolding and translocation by an ATP-fueled proteolytic machine","volume":"145","author":"Aubin-Tam","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0245","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0250","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2005477","article-title":"SARS-Cov-2 \u2014 The search for effective therapy","author":"Baden","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0255","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb0260","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0960-9822(03)00417-2","article-title":"Proteasome disassembly and downregulation is correlated with viability during stationary phase","volume":"13","author":"Bajorek","year":"2003","journal-title":"Current Biology: CB"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb0265","first-page":"1579","article-title":"Keepers at the final gates: Regulatory complexes and gating of the proteasome channel","volume":"61","author":"Bajorek","year":"2004","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"5865","key":"10.1016\/j.pharmthera.2020.107579_bb0270","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0275","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","article-title":"The NF-kappa B and I kappa B proteins: new discoveries and insights","volume":"14","author":"Baldwin","year":"1996","journal-title":"Annual Review of Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI11991","article-title":"Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB","volume":"107","author":"Baldwin","year":"2001","journal-title":"The Journal of Clinical Investigation"},{"issue":"32","key":"10.1016\/j.pharmthera.2020.107579_bb0285","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1073\/pnas.1806797115","article-title":"Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0290","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"The American Journal of Surgical Pathology"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb0295","doi-asserted-by":"crossref","first-page":"21527","DOI":"10.18632\/oncotarget.7596","article-title":"Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition","volume":"7","author":"Banno","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0300","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annual Review of Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0305","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb0310","first-page":"E1001","article-title":"Dual functions of the Hsm3 protein in chaperoning and scaffolding regulatory particle subunits during the proteasome assembly","volume":"109","author":"Barrault","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0315","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0320","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/21623945.2019.1607423","article-title":"PNPLA3-I148M: A problem of plenty in non-alcoholic fatty liver disease","volume":"8","author":"Basu Ray","year":"2019","journal-title":"Adipocyte"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0325","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jmb.2008.12.081","article-title":"Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination","volume":"386","author":"Baugh","year":"2009","journal-title":"Journal of Molecular Biology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2020.107579_bb0330","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-5793(88)81069-X","article-title":"Electron microscopy and image analysis of the multicatalytic proteinase","volume":"241","author":"Baumeister","year":"1988","journal-title":"FEBS Letters"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb0335","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington's disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"issue":"37","key":"10.1016\/j.pharmthera.2020.107579_bb0340","doi-asserted-by":"crossref","first-page":"14870","DOI":"10.1073\/pnas.1213333109","article-title":"Near-atomic resolution structural model of the yeast 26S proteasome","volume":"109","author":"Beck","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb0345","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nsmb.2659","article-title":"Reconstitution of the 26S proteasome reveals functional asymmetries in its AAA+ unfoldase","volume":"20","author":"Beckwith","year":"2013","journal-title":"Nature Structural & Molecular Biology"},{"issue":"33","key":"10.1016\/j.pharmthera.2020.107579_bb0350","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1523\/JNEUROSCI.2218-08.2008","article-title":"Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies","volume":"28","author":"Bedford","year":"2008","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0355","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20040544","article-title":"Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology","volume":"382","author":"Beinke","year":"2004","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0360","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0365","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/cne.10652","article-title":"Melanopsin retinal ganglion cells receive bipolar and amacrine cell synapses","volume":"460","author":"Belenky","year":"2003","journal-title":"The Journal of Comparative Neurology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0370","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1039\/C8SC03394C","article-title":"Ubiquitin binds the amyloid \u03b2 peptide and interferes with its clearance pathways","volume":"10","author":"Bellia","year":"2019","journal-title":"Chemical Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0375","first-page":"286","article-title":"Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis","volume":"34","author":"Benbrook","year":"2012","journal-title":"Experimental Oncology"},{"issue":"5521","key":"10.1016\/j.pharmthera.2020.107579_bb0380","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the ubiquitin-proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science (New York, N.Y.)"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0385","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/biom4030862","article-title":"Regulating the 20S proteasome ubiquitin-independent degradation pathway","volume":"4","author":"Ben-Nissan","year":"2014","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JPD-160921","article-title":"The proteasome inhibition model of Parkinson's disease","volume":"7","author":"Bentea","year":"2017","journal-title":"Journal of Parkinson's Disease"},{"issue":"27","key":"10.1016\/j.pharmthera.2020.107579_bb0395","doi-asserted-by":"crossref","first-page":"15949","DOI":"10.1016\/S0021-9258(18)71571-8","article-title":"Degradation of ornithine decarboxylase in reticulocyte lysate is ATP-dependent but ubiquitin-independent","volume":"264","author":"Bercovich","year":"1989","journal-title":"Journal of Biological Chemistry"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb0400","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb0405","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-06-1812","article-title":"A phase I\/II study of arsenic trioxide\/bortezomib\/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma","volume":"13","author":"Berenson","year":"2007","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0410","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1167\/iovs.06-1029","article-title":"Retinal abnormalities in early Alzheimer's disease","volume":"48","author":"Berisha","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"10 Pt B","key":"10.1016\/j.pharmthera.2020.107579_bb0415","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.bbalip.2017.06.006","article-title":"Establishing the lipid droplet proteome: Mechanisms of lipid droplet protein targeting and degradation","volume":"1862","author":"Bersuker","year":"2017","journal-title":"Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0420","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chemical Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0425","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb0430","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1073\/pnas.1402215111","article-title":"Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A","volume":"111","author":"Bhat","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0435","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0092-8674(81)90233-6","article-title":"The selective degradation of injected proteins occurs principally in the cytosol rather than in lysosomes","volume":"25","author":"Bigelow","year":"1981","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0440","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.neuropharm.2004.07.028","article-title":"A proteasome-sensitive connection between PSD-95 and GluR1 endocytosis","volume":"47","author":"Bingol","year":"2004","journal-title":"Neuropharmacology"},{"issue":"7097","key":"10.1016\/j.pharmthera.2020.107579_bb0445","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature04769","article-title":"Activity-dependent dynamics and sequestration of proteasomes in dendritic spines","volume":"441","author":"Bingol","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0450","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cell.2010.01.024","article-title":"Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines","volume":"140","author":"Bingol","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010210","article-title":"Interplay between autophagy and the ubiquitin-proteasome system and its role in the pathogenesis of age-related macular degeneration","volume":"20","author":"Blasiak","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0460","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.biophys.28.1.295","article-title":"The proteasome","volume":"28","author":"Bochtler","year":"1999","journal-title":"Annual Review of Biophysics and Biomolecular Structure"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb0465","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1074-5521(98)90169-7","article-title":"Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes","volume":"5","author":"Bogyo","year":"1998","journal-title":"Chemistry & Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0470","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbrc.2013.04.069","article-title":"Localization of the regulatory particle subunit Sem1 in the 26S proteasome","volume":"435","author":"Bohn","year":"2013","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0475","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2018.109","article-title":"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing","volume":"17","author":"Boland","year":"2018","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb0480","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1111\/j.1742-4658.2008.06696.x","article-title":"Natural polyphenols as proteasome modulators and their role as anti-cancer compounds","volume":"275","author":"Bonfili","year":"2008","journal-title":"FEBS Journal"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0485","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","article-title":"Safety of ixazomib for the treatment of multiple myeloma","volume":"16","author":"Bonnet","year":"2017","journal-title":"Expert Opinion on Drug Safety"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0490","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cr0502504","article-title":"20S proteasome and its inhibitors: Crystallographic knowledge for drug development","volume":"107","author":"Borissenko","year":"2007","journal-title":"Chemical Reviews"},{"issue":"47","key":"10.1016\/j.pharmthera.2020.107579_bb0495","doi-asserted-by":"crossref","first-page":"19209","DOI":"10.1074\/jbc.M117.815126","article-title":"An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons","volume":"292","author":"Boselli","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"issue":"6555","key":"10.1016\/j.pharmthera.2020.107579_bb0500","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/378416a0","article-title":"A protein catalytic framework with an N-terminal nucleophile is capable of self-activation","volume":"378","author":"Brannigan","year":"1995","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0505","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.cdd.4401874","article-title":"Targeting NF-kappaB in hematologic malignancies","volume":"13","author":"Braun","year":"2006","journal-title":"Cell Death and Differentiation"},{"issue":"7113","key":"10.1016\/j.pharmthera.2020.107579_bb0510","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nature05293","article-title":"Cell death in the nervous system","volume":"443","author":"Bredesen","year":"2006","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb0515","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","article-title":"Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production","volume":"125","author":"Brehm","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0520","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nature Reviews. Neuroscience"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0525","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clml.2017.05.003","article-title":"New Agents in Multiple Myeloma: An\u202fExamination of Safety Profiles","volume":"17","author":"Bringhen","year":"2017","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb0530","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","article-title":"Awakening guardian angels: drugging the p53 pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nature Reviews. Cancer"},{"issue":"6549","key":"10.1016\/j.pharmthera.2020.107579_bb0535","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/377552a0","article-title":"Radiation-induced cell cycle arrest compromised by p21 deficiency","volume":"377","author":"Brugarolas","year":"1995","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.pharmthera.2020.107579_bb0540","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41388-018-0357-2","article-title":"Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development","volume":"37","author":"Bruggeman","year":"2018","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb0545","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1002\/anie.201509092","article-title":"A set of activity-based probes to visualize human (immuno)proteasome activities","volume":"55","author":"de Bruin","year":"2016","journal-title":"Angewandte Chemie (International Ed. in. English)"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb0550","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From bortezomib to other inhibitors of the proteasome and beyond","volume":"19","author":"Buac","year":"2013","journal-title":"Current Pharmaceutical Design"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb0555","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jmb.2017.05.027","article-title":"Proteasome structure and assembly","volume":"429","author":"Budenholzer","year":"2017","journal-title":"Journal of Molecular Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb0560","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/en.2017-00592","article-title":"Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice","volume":"158","author":"Bullova","year":"2017","journal-title":"Endocrinology"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb0565","doi-asserted-by":"crossref","first-page":"10348","DOI":"10.1073\/pnas.190268597","article-title":"Identification and characterization of a mammalian protein interacting with 20S proteasome precursors","volume":"97","author":"Burri","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2018.00126","article-title":"Interplay between the autophagy-lysosomal pathway and the ubiquitin-proteasome system: A target for therapeutic development in alzheimer's disease","volume":"12","author":"Bustamante","year":"2018","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0575","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.bbrc.2004.08.195","article-title":"Effects of donor age on proteasome activity and senescence in trabecular meshwork cells","volume":"323","author":"Caballero","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0580","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0006-291X(03)01385-8","article-title":"Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells","volume":"308","author":"Caballero","year":"2003","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0585","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tibs.2006.01.006","article-title":"Heat shock proteins in cancer: Chaperones of tumorigenesis","volume":"31","author":"Calderwood","year":"2006","journal-title":"Trends in Biochemical Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0590","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12035-012-8391-5","article-title":"The ubiquitin-proteasome system in retinal health and disease","volume":"47","author":"Campello","year":"2013","journal-title":"Molecular Neurobiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0595","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: Evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0600","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neulet.2019.03.016","article-title":"Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer's disease pathogenesis","volume":"703","author":"Cao","year":"2019","journal-title":"Neuroscience Letters"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0605","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nature Clinical Practice. Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb0610","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1021\/bi00187a014","article-title":"Evidence that the nature of amino acid residues in the P3 position directs substrates to distinct catalytic sites of the pituitary multicatalytic proteinase complex (proteasome)","volume":"33","author":"Cardozo","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0615","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.201600488","article-title":"High-resolution snapshots of proteasome inhibitors in action revise inhibition paradigms and inspire next-generation inhibitor design","author":"Carmony","year":"2016","journal-title":"Chembiochem: A European Journal of Chemical Biology."},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224982","article-title":"Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution","volume":"14","author":"Carnevale","year":"2019","journal-title":"PLoS One"},{"issue":"9071","key":"10.1016\/j.pharmthera.2020.107579_bb0625","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(97)02073-4","article-title":"Conformational disease","volume":"350","author":"Carrell","year":"1997","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0630","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-4939-3756-1_2","article-title":"Review and literature mining on proteostasis factors and cancer","volume":"1449","author":"Carvalho","year":"2016","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0635","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/biom4020566","article-title":"PA28\u03b1\u03b2: The enigmatic magic ring of the proteasome?","volume":"4","author":"Cascio","year":"2014","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb0640","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/emboj\/21.11.2636","article-title":"Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes","volume":"21","author":"Cascio","year":"2002","journal-title":"The EMBO Journal"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb0645","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/emboj\/20.10.2357","article-title":"26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide","volume":"20","author":"Cascio","year":"2001","journal-title":"The EMBO Journal"},{"issue":"9758","key":"10.1016\/j.pharmthera.2020.107579_bb0650","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0655","first-page":"1209","article-title":"Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes","author":"Cecarini","year":"2008","journal-title":"Brain Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0660","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opinion on Drug Safety"},{"issue":"5880","key":"10.1016\/j.pharmthera.2020.107579_bb0665","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.1153252","article-title":"MeCP2, a key contributor to neurological disease, activates and represses transcription","volume":"320","author":"Chahrour","year":"2008","journal-title":"Science (New York, N.Y.)"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb0670","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809014","article-title":"USP14 inhibition corrects an in\u202fvivo model of impaired mitophagy","volume":"10","author":"Chakraborty","year":"2018","journal-title":"EMBO Molecular Medicine"},{"issue":"29","key":"10.1016\/j.pharmthera.2020.107579_bb0675","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0680","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbcan.2018.08.002","article-title":"Ubiquitination and SUMOylation in the chronic inflammatory tumor microenvironment","volume":"1870","author":"Chang","year":"2018","journal-title":"Biochimica Et Biophysica Acta. Reviews on Cancer"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0685","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: Possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb0690","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/emboj.2011.204","article-title":"Autoregulation of Parkin activity through its ubiquitin-like domain","volume":"30","author":"Chaugule","year":"2011","journal-title":"The EMBO Journal"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0695","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0700","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.pharmtox.45.120403.100037","article-title":"Proteasome inhibition in multiple myeloma: therapeutic implication","volume":"45","author":"Chauhan","year":"2005","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb0705","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0710","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","volume":"115","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb0715","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb0720","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2007.05.022","article-title":"Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome","volume":"26","author":"Chen","year":"2007","journal-title":"Molecular Cell"},{"issue":"48","key":"10.1016\/j.pharmthera.2020.107579_bb0725","doi-asserted-by":"crossref","first-page":"17505","DOI":"10.1523\/JNEUROSCI.2922-11.2011","article-title":"Ubiquitin homeostasis is critical for synaptic development and function","volume":"31","author":"Chen","year":"2011","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb0730","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb0735","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bcp.2005.02.022","article-title":"Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells","volume":"69","author":"Chen","year":"2005","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0740","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Current Cancer Drug Targets"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb0745","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1101\/gad.9.13.1586","article-title":"Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway","volume":"9","author":"Chen","year":"1995","journal-title":"Genes & Development"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb0750","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/j.1460-2075.1995.tb07260.x","article-title":"Biogenesis, structure and function of the yeast 20S proteasome","volume":"14","author":"Chen","year":"1995","journal-title":"The EMBO Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb0755","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0092-8674(00)80171-3","article-title":"Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly","volume":"86","author":"Chen","year":"1996","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb0760","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-05-0201","article-title":"Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0765","doi-asserted-by":"crossref","first-page":"a004374","DOI":"10.1101\/cshperspect.a004374","article-title":"Cellular strategies of protein quality control","volume":"3","author":"Chen","year":"2011","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0770","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.06.023","article-title":"The ubiquitin\u2013proteasome system and its potential application in hepatocellular carcinoma therapy","volume":"379","author":"Chen","year":"2016","journal-title":"Cancer Letters"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0775","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrc991","article-title":"Inhibiting the p53-MDM2 interaction: an important target for cancer therapy","volume":"3","author":"Ch\u00e8ne","year":"2003","journal-title":"Nature Reviews. Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb0780","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfv222","article-title":"Bortezomib-induced acute interstitial nephritis","volume":"30","author":"Cheungpasitporn","year":"2015","journal-title":"Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0785","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0790","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annual Review of Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0795","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bjh.13304","article-title":"Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstr\u00f6m macroglobulinaemia tumour cells","volume":"169","author":"Chitta","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0800","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1038\/ncomms10963","article-title":"Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation","volume":"7","author":"Choi","year":"2016","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0805","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/s41467-018-04774-9","article-title":"mTORC1 accelerates retinal development via the immunoproteasome","volume":"9","author":"Choi","year":"2018","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0810","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/B:BGEN.0000017687.55667.42","article-title":"Proteasome inhibition induces a senescence-like phenotype in primary human fibroblasts cultures","volume":"5","author":"Chondrogianni","year":"2004","journal-title":"Biogerontology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0815","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.exger.2007.01.012","article-title":"Overexpression of hUMP1\/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence","volume":"42","author":"Chondrogianni","year":"2007","journal-title":"Experimental Gerontology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0820","series-title":"Protein Metabolism and Homeostasis in Aging","first-page":"38","article-title":"Proteasome function determines cellular homeostasis and the rate of aging","author":"Chondrogianni","year":"2010"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb0825","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.exger.2010.07.001","article-title":"Anti-ageing and rejuvenating effects of quercetin","volume":"45","author":"Chondrogianni","year":"2010","journal-title":"Experimental Gerontology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0830","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0835","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: From the lysosome to ubiquitin and the proteasome","volume":"6","author":"Ciechanover","year":"2005","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb0840","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1016\/j.bmc.2013.01.056","article-title":"Intracellular protein degradation: From a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting","volume":"21","author":"Ciechanover","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0845","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","article-title":"The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg","volume":"40","author":"Ciechanover","year":"2003","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0850","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0092-8674(84)90300-3","article-title":"Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85","volume":"37","author":"Ciechanover","year":"1984","journal-title":"Cell"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2020.107579_bb0855","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0300-9084(01)01239-1","article-title":"Mechanisms of ubiquitin-mediated, limited processing of the NF-kappaB1 precursor protein p105","volume":"83","author":"Ciechanover","year":"2001","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0860","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1073\/pnas.77.3.1365","article-title":"ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation","volume":"77","author":"Ciechanover","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0865","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbrc.2012.08.025","article-title":"A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. 1978","volume":"425","author":"Ciechanover","year":"2012","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0870","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fnins.2017.00185","article-title":"Protein quality control by molecular chaperones in neurodegeneration","volume":"11","author":"Ciechanover","year":"2017","journal-title":"Frontiers in Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0875","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0006-291X(78)91249-4","article-title":"A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes","volume":"81","author":"Ciehanover","year":"1978","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0880","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.celrep.2019.01.096","article-title":"Filamentous aggregates are fragmented by the proteasome holoenzyme","volume":"26","author":"Cliffe","year":"2019","journal-title":"Cell Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0885","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10555-017-9699-4","article-title":"(Immuno)proteasomes as therapeutic target in acute leukemia","volume":"36","author":"Cloos","year":"2017","journal-title":"Cancer Metastasis Reviews"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0890","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/17425247.2016.1178234","article-title":"Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: An in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells","volume":"13","author":"Coelho","year":"2016","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0895","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bmcl.2018.12.030","article-title":"Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators","volume":"29","author":"Coleman","year":"2019","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb0900","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0896-6273(03)00687-1","article-title":"Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression","volume":"40","author":"Colledge","year":"2003","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb0905","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"issue":"38","key":"10.1016\/j.pharmthera.2020.107579_bb0910","doi-asserted-by":"crossref","first-page":"29179","DOI":"10.1074\/jbc.R000010200","article-title":"O-glycosylation of nuclear and cytosolic proteins dynamic interplay between O-GlcNAc ando-phosphate","volume":"275","author":"Comer","year":"2000","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb0915","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.onc.1209974","article-title":"Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53\/PUMA pathway","volume":"26","author":"Concannon","year":"2007","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb0920","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s12035-018-1157-y","article-title":"Resveratrol induces brain resilience against Alzheimer neurodegeneration through proteostasis enhancement","volume":"56","author":"Corpas","year":"2019","journal-title":"Molecular Neurobiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb0925","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/1078-0432.CCR-13-2658","article-title":"Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses","volume":"20","author":"Coughlin","year":"2014","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0930","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","article-title":"Structure and functions of the 20S and 26S proteasomes","volume":"65","author":"Coux","year":"1996","journal-title":"Annual Review of Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0935","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2999-1","article-title":"Molecular chess? Hallmarks of anti-cancer drug resistance","volume":"17","author":"Cree","year":"2017","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb0940","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1074\/jbc.M512786200","article-title":"Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation","volume":"281","author":"Cripps","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb0945","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073710","article-title":"Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer","volume":"8","author":"Cron","year":"2013","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194666","article-title":"Natural products as modulators of the proteostasis machinery: Implications in neurodegenerative diseases","volume":"20","author":"Cuanalo-Contreras","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0955","doi-asserted-by":"crossref","first-page":"14506","DOI":"10.1038\/s41598-019-50857-y","article-title":"Ubiquitin receptors are required for substrate-mediated activation of the proteasome's unfolding ability","volume":"9","author":"Cundiff","year":"2019","journal-title":"Scientific Reports"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb0960","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1016\/j.febslet.2005.06.003","article-title":"Parkin interacts with the proteasome subunit alpha4","volume":"579","author":"D\u00e4chsel","year":"2005","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0965","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2015.12.012","article-title":"Mammalian proteasome subtypes: Their diversity in structure and function","volume":"591","author":"Dahlmann","year":"2016","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"4\u20136","key":"10.1016\/j.pharmthera.2020.107579_bb0970","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000468685","article-title":"In vitro activation of the 20S proteasome","volume":"47","author":"Dahlmann","year":"1993","journal-title":"Enzyme & Protein"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0975","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/bj2280171","article-title":"Activation of the multicatalytic proteinase from rat skeletal muscle by fatty acids or sodium dodecyl sulphate","volume":"228","author":"Dahlmann","year":"1985","journal-title":"Biochemical Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb0980","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ajhg.2010.02.018","article-title":"A single-nucleotide deletion in the POMP 5\u2019 UTR causes a transcriptional switch and altered epidermal proteasome distribution in KLICK genodermatosis","volume":"86","author":"Dahlqvist","year":"2010","journal-title":"American Journal of Human Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb0985","doi-asserted-by":"crossref","first-page":"e29471","DOI":"10.1371\/journal.pone.0029471","article-title":"siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis","volume":"7","author":"Dahlqvist","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb0990","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1002\/jcp.24017","article-title":"Proteotoxic stress of cancer: Implication of the heat-shock response in oncogenesis","volume":"227","author":"Dai","year":"2012","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb0995","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.freeradbiomed.2013.11.017","article-title":"Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation","volume":"67","author":"Dal Vechio","year":"2014","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1000","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13027","article-title":"Atomic structure of the 26S proteasome lid reveals the mechanism of deubiquitinase inhibition","volume":"5","author":"Dambacher","year":"2016","journal-title":"ELife"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1005","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bcp.2003.10.031","article-title":"Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells","volume":"67","author":"Daniel","year":"2004","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnmol.2014.00070","article-title":"The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution","volume":"7","author":"Dantuma","year":"2014","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD\u00ae\u202fimmunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"D'Arcy","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb1025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145333","article-title":"Reduced levels of proteasome products in a mouse striatal cell model of Huntington's disease","volume":"10","author":"Dasgupta","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1030","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1038\/s41598-017-17008-7","article-title":"Electrostatic map of proteasome \u03b1-rings encodes the design of allosteric porphyrin-based inhibitors able to affect 20S conformation by cooperative binding","volume":"7","author":"Di Dato","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1471-4159.2002.01137.x","article-title":"Proteasomal degradation of tau protein","volume":"83","author":"David","year":"2002","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1042\/bst0210346","article-title":"Protein modification by oxidants and the role of proteolytic enzymes","volume":"21","author":"Davies","year":"1993","journal-title":"Biochemical Society Transactions"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2020.107579_bb1045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0300-9084(01)01250-0","article-title":"Degradation of oxidized proteins by the 20S proteasome","volume":"83","author":"Davies","year":"2001","journal-title":"Biochimie"},{"issue":"4390","key":"10.1016\/j.pharmthera.2020.107579_bb1050","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/1721143a0","article-title":"Enzymic content of the mitochondria fraction","volume":"172","author":"De Duve","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.ph.28.030166.002251","article-title":"Functions of lysosomes","volume":"28","author":"De Duve","year":"1966","journal-title":"Annual Review of Physiology"},{"issue":"41","key":"10.1016\/j.pharmthera.2020.107579_bb1060","doi-asserted-by":"crossref","first-page":"29467","DOI":"10.1074\/jbc.M113.491662","article-title":"The proteasome-associated protein Ecm29 inhibits proteasomal ATPase activity and in vivo protein degradation by the proteasome","volume":"288","author":"De La Mota-Peynado","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/nmt.14.19","article-title":"Retinal manifestations of Alzheimer's disease","volume":"4","author":"Dehabadi","year":"2014","journal-title":"Neurodegenerative Disease Management"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb1070","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Research"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb1075","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1073\/pnas.1714938115","article-title":"Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses","volume":"115","author":"Deng","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90039-X","article-title":"Mice lacking p21CIP1\/WAF1 undergo normal development, but are defective in G1 checkpoint control","volume":"82","author":"Deng","year":"1995","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb1085","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1038\/emboj.2011.224","article-title":"Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry","volume":"30","author":"Deriziotis","year":"2011","journal-title":"The EMBO Journal"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb1090","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4161\/cc.29335","article-title":"Cellular senescence and protein degradation","volume":"13","author":"Desch\u00eanes-Simard","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12915-014-0094-0","article-title":"Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy","volume":"12","author":"Deshaies","year":"2014","journal-title":"BMC Biology"},{"issue":"44","key":"10.1016\/j.pharmthera.2020.107579_bb1100","doi-asserted-by":"crossref","first-page":"32208","DOI":"10.1074\/jbc.M704870200","article-title":"Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus","volume":"282","author":"Devaraj","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1105","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1016\/S0021-9258(17)37244-7","article-title":"A 26 S protease subunit that binds ubiquitin conjugates","volume":"269","author":"Deveraux","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb1110","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.2174\/1381612811319180009","article-title":"Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy","volume":"19","author":"Devine","year":"2013","journal-title":"Current Pharmaceutical Design"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1115","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: Ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1471-4159.2006.03968.x","article-title":"Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain","volume":"98","author":"D\u00edaz-Hern\u00e1ndez","year":"2006","journal-title":"Journal of Neurochemistry"},{"issue":"40","key":"10.1016\/j.pharmthera.2020.107579_bb1125","doi-asserted-by":"crossref","first-page":"25637","DOI":"10.1074\/jbc.273.40.25637","article-title":"Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants","volume":"273","author":"Dick","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1130","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1172\/JCI29715","article-title":"The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins","volume":"117","author":"Dickey","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1947601910382902","article-title":"Ubiquitin-dependent proteolysis in G1\/S phase control and its relationship with tumor susceptibility","volume":"1","author":"Diehl","year":"2010","journal-title":"Genes & Cancer"},{"issue":"5334","key":"10.1016\/j.pharmthera.2020.107579_bb1140","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science (New York, N.Y.)"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1145","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"The Lancet. Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"The Lancet. Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1160","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Advances"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2018-06-860015","article-title":"Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR","volume":"133","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1006\/jmbi.1998.1818","article-title":"Conformational constraints for protein self-cleavage in the proteasome","volume":"279","author":"Ditzel","year":"1998","journal-title":"Journal of Molecular Biology"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb1175","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1523\/JNEUROSCI.4427-11.2012","article-title":"Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons","volume":"32","author":"Djakovic","year":"2012","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"39","key":"10.1016\/j.pharmthera.2020.107579_bb1180","doi-asserted-by":"crossref","first-page":"26655","DOI":"10.1074\/jbc.M109.021956","article-title":"Regulation of the proteasome by neuronal activity and calcium\/calmodulin-dependent protein kinase II","volume":"284","author":"Djakovic","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.molcel.2009.04.030","article-title":"Structure and activity of the N-terminal substrate recognition domains in proteasomal ATPases","volume":"34","author":"Djuranovic","year":"2009","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1190","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010004","article-title":"The autophagy-lysosomal pathways and their emerging roles in modulating proteostasis in tumors","volume":"8","author":"Dong","year":"2018","journal-title":"Cells"},{"issue":"7737","key":"10.1016\/j.pharmthera.2020.107579_bb1195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-018-0736-4","article-title":"Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome","volume":"565","author":"Dong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1200","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16567","article-title":"Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial","author":"Doorduijn","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1205","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/jm7010589","article-title":"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer","volume":"51","author":"Dorsey","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1210","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1080\/10428194.2017.1365855","volume":"59","author":"Drach","year":"2018","journal-title":"Leukemia & Lymphoma"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1215","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3892\/ol.2016.4213","article-title":"Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature","volume":"11","author":"Du","year":"2016","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcancer.2015.04.003","article-title":"ER proteostasis addiction in cancer biology: Novel concepts","volume":"33","author":"Dufey","year":"2015","journal-title":"Seminars in Cancer Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1225","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ph11020044","article-title":"Old drugs as new treatments for neurodegenerative diseases","volume":"11","author":"Dur\u00e3es","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"10068","key":"10.1016\/j.pharmthera.2020.107579_bb1230","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1235","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1042\/bj0600604","article-title":"Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue","volume":"60","author":"de Duve","year":"1955","journal-title":"Biochemical Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm1589","article-title":"Intrinsically unstructured proteins and their functions","volume":"6","author":"Dyson","year":"2005","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.10699","article-title":"Cell cycle checkpoints and their impact on anticancer therapeutic strategies","volume":"91","author":"Eastman","year":"2004","journal-title":"Journal of Cellular Biochemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1250","first-page":"489","article-title":"Citicoline in the treatment of Parkinson's disease","volume":"12","author":"Eberhardt","year":"1990","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1255","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.3389\/fimmu.2019.02756","article-title":"Contribution of the unfolded protein response (UPR) to the pathogenesis of proteasome-associated autoinflammatory syndromes (PRAAS)","volume":"10","author":"Ebstein","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1260","doi-asserted-by":"crossref","unstructured":"Ehlinger, A., Park, S., Fahmy, A., Lary, J. W., Cole, J. L., Finley, D., & Walters, K. J. (2013). Conformational dynamics of the Rpt6 ATPase in proteasome assembly and Rpn14 binding. Structure (London, England: 1993), 21(5), 753\u2013765. https:\/\/doi.org\/10.1016\/j.str.2013.02.021.","DOI":"10.1016\/j.str.2013.02.021"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1265","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.celrep.2018.07.004","article-title":"Expanded coverage of the 26S proteasome conformational landscape reveals mechanisms of peptidase gating","volume":"24","author":"Eisele","year":"2018","journal-title":"Cell Reports"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb1270","doi-asserted-by":"crossref","first-page":"26817","DOI":"10.1074\/jbc.M404020200","article-title":"Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome","volume":"279","author":"Elsasser","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1275","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","article-title":"Unexpected cardiotoxicity in haematological bortezomib treated patients","volume":"138","author":"Enrico","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1280","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbamcr.2013.05.008","article-title":"Ubiquitin-independent proteasomal degradation","volume":"1843","author":"Erales","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb1285","doi-asserted-by":"crossref","first-page":"18535","DOI":"10.1074\/jbc.M112.357327","article-title":"Functional asymmetries of proteasome translocase pore","volume":"287","author":"Erales","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1290","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ncb2838","article-title":"Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress","volume":"15","author":"Escusa-Toret","year":"2013","journal-title":"Nature Cell Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb1295","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/ajt.14435","article-title":"The immunoproteasome: An old player with a novel and emerging role in alloimmunity","volume":"17","author":"Eskandari","year":"2017","journal-title":"American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb1300","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.str.2013.06.023","article-title":"Formation of an intricate helical bundle dictates the assembly of the 26S proteasome lid","volume":"21","author":"Estrin","year":"2013","journal-title":"Structure (London, England: 1993)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1073\/pnas.74.1.54","article-title":"A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes","volume":"74","author":"Etlinger","year":"1977","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1310","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1016\/S0021-9258(19)85530-8","article-title":"Control of protein degradation in reticulocytes and reticulocyte extracts by hemin","volume":"255","author":"Etlinger","year":"1980","journal-title":"Journal of Biological Chemistry"},{"issue":"6835","key":"10.1016\/j.pharmthera.2020.107579_bb1315","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/35077213","article-title":"Proliferation, cell cycle and apoptosis in cancer","volume":"411","author":"Evan","year":"2001","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb1320","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1073\/pnas.86.20.7751","article-title":"ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin","volume":"86","author":"Eytan","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1325","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1021\/pr500193k","article-title":"Label-free quantitative proteomics reveals the dynamics of proteasome complexes composition and stoichiometry in a wide range of human cell lines","volume":"13","author":"Fabre","year":"2014","journal-title":"Journal of Proteome Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1330","doi-asserted-by":"crossref","first-page":"100767","DOI":"10.1016\/j.preteyeres.2019.06.003","article-title":"Cholinergic nervous system and glaucoma: From basic science to clinical applications","volume":"72","author":"Faiq","year":"2019","journal-title":"Progress in Retinal and Eye Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1335","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.neuron.2013.08.004","article-title":"Noncanonical FK506-binding protein BDBT binds DBT to enhance its circadian function and forms foci at night","volume":"80","author":"Fan","year":"2013","journal-title":"Neuron"},{"issue":"6352","key":"10.1016\/j.pharmthera.2020.107579_bb1340","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/354395a0","article-title":"Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway","volume":"354","author":"Fan","year":"1991","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1345","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/embr.201337294","article-title":"Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy","volume":"15","author":"Fedorowicz","year":"2014","journal-title":"EMBO Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1350","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angewandte Chemie (International Ed. in English)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.redox.2018.09.011","article-title":"Loss of NRF-2 and PGC-1\u03b1 genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration","volume":"20","author":"Felszeghy","year":"2019","journal-title":"Redox Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1360","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","article-title":"Discovery and development of the anticancer agent salinosporamide A (NPI-0052)","volume":"17","author":"Fenical","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb1365","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1158\/0008-5472.CAN-05-0686","article-title":"Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications","volume":"65","author":"Fern\u00e1ndez","year":"2005","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1370","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1038\/s41598-018-28143-0","article-title":"C3a triggers formation of sub-retinal pigment epithelium deposits via the ubiquitin proteasome pathway","volume":"8","author":"Fernandez-Godino","year":"2018","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1375","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: Basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1380","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","article-title":"Immunoproteasomes: Structure, function, and antigen presentation","volume":"109","author":"Ferrington","year":"2012","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1385","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annual Review of Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1390","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tibs.2015.10.009","article-title":"Gates, channels, and switches: Elements of the proteasome machine","volume":"41","author":"Finley","year":"2016","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1395","first-page":"a033985","article-title":"The proteasome and its network: Engineering for adaptability","author":"Finley","year":"2019","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb1400","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1096\/fj.03-0205com","article-title":"Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain","volume":"17","author":"Fischer","year":"2003","journal-title":"The FASEB Journal"},{"issue":"30","key":"10.1016\/j.pharmthera.2020.107579_bb1405","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1410","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb1415","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chembiol.2010.05.027","article-title":"Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t","volume":"17","author":"Florea","year":"2010","journal-title":"Chemistry & Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1420","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0003-9861(88)90067-7","article-title":"Multicatalytic proteinase in fish muscle","volume":"267","author":"Folco","year":"1988","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1425","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuron.2006.08.015","article-title":"A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP","volume":"52","author":"Fonseca","year":"2006","journal-title":"Neuron"},{"issue":"34","key":"10.1016\/j.pharmthera.2020.107579_bb1430","doi-asserted-by":"crossref","first-page":"30542","DOI":"10.1074\/jbc.M414126200","article-title":"Proteasome-mediated degradation of STAT1alpha following infection of macrophages with Leishmania donovani","volume":"280","author":"Forget","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb1435","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1093\/emboj\/cdg436","article-title":"The pore of activated 20S proteasomes has an ordered 7-fold symmetric conformation","volume":"22","author":"F\u00f6rster","year":"2003","journal-title":"The EMBO Journal"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1440","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/bi035894p","article-title":"Structural determinants for the intracellular degradation of human thymidylate synthase","volume":"43","author":"Forsthoefel","year":"2004","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1445","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/gbe\/evv068","article-title":"Evolution of proteasome regulators in eukaryotes","volume":"7","author":"Fort","year":"2015","journal-title":"Genome Biology and Evolution"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1450","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: Current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discovery Today"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb1455","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/sj.embor.7401091","article-title":"The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum","volume":"8","author":"Fricke","year":"2007","journal-title":"EMBO Reports"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1460","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome Inhibitor Drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1465","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0952-7915(99)80014-4","article-title":"Antigen presentation by MHC class I and its regulation by interferon gamma","volume":"11","author":"Fr\u00fch","year":"1999","journal-title":"Current Opinion in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb1470","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1002\/cam4.1770","article-title":"USP14 as a novel prognostic marker promotes cisplatin resistance via Akt\/ERK signaling pathways in gastric cancer","volume":"7","author":"Fu","year":"2018","journal-title":"Cancer Medicine"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb1475","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1097\/00001756-200112040-00046","article-title":"Photic regulation of melatonin in rat retina and the role of proteasomal proteolysis","volume":"12","author":"Fukuhara","year":"2001","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1480","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.bbrc.2010.05.061","article-title":"Dissection of the assembly pathway of the proteasome lid in Saccharomyces cerevisiae","volume":"396","author":"Fukunaga","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1485","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2009.04.061","article-title":"Multiple assembly chaperones govern biogenesis of the proteasome regulatory particle base","volume":"137","author":"Funakoshi","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1490","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.13101","article-title":"Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma","volume":"168","author":"Furtado","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1495","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","article-title":"Redundant angiogenic signaling and tumor drug resistance","volume":"36","author":"Gacche","year":"2018","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb1500","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1089\/ars.2013.5816","article-title":"Harnessing proteasome dynamics and allostery in drug design","volume":"21","author":"Gaczynska","year":"2014","journal-title":"Antioxidants & Redox Signaling"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1505","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Gallerani","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1510","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1515","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/15548627.2016.1147667","article-title":"Cytosolic PINK1 promotes the targeting of ubiquitinated proteins to the aggresome-autophagy pathway during proteasomal stress","volume":"12","author":"Gao","year":"2016","journal-title":"Autophagy"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb1520","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb1525","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.2174\/1381612811319220015","article-title":"Drug combinations with proteasome inhibitors in antitumor therapy","volume":"19","author":"Gatti","year":"2013","journal-title":"Current Pharmaceutical Design"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb1530","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-18-3728","article-title":"A phase Ib\/II study of oprozomib in patients with advanced multiple myeloma and Waldenstr\u00f6m macroglobulinemia","volume":"25","author":"Ghobrial","year":"2019","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington's disease","volume":"5","author":"Giamp\u00e0","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1540","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hed.23046","volume":"35","author":"Gilbert","year":"2013","journal-title":"Head & Neck"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1545","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and multiple myeloma","volume":"4","author":"Giuliani","year":"2011","journal-title":"Cancer Microenvironment"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1550","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/abbi.1994.1245","article-title":"Exposure of hydrophobic moieties promotes the selective degradation of hydrogen peroxide-modified hemoglobin by the multicatalytic proteinase complex, proteasome","volume":"311","author":"Giulivi","year":"1994","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1555","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1021\/acs.jmedchem.8b01025","article-title":"Proline- and arginine-rich peptides as flexible allosteric modulators of human proteasome activity","volume":"62","author":"Gi\u017cy\u0144ska","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1560","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1565","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiological Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1570","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tins.2010.04.003","article-title":"The propagation of prion-like protein inclusions in neurodegenerative diseases","volume":"33","author":"Goedert","year":"2010","journal-title":"Trends in Neurosciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1575","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1073\/pnas.69.2.422","article-title":"Degradation of abnormal proteins in Escherichia coli (protein breakdown-protein structure-mistranslation-amino acid analogs-puromycin)","volume":"69","author":"Goldberg","year":"1972","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1580","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev.bi.45.070176.003531","article-title":"Intracellular protein degradation in mammalian and bacterial cells: Part 2","volume":"45","author":"Goldberg","year":"1976","journal-title":"Annual Review of Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.molcel.2015.07.005","article-title":"Blocking cancer growth with less POMP or proteasomes","volume":"59","author":"Goldberg","year":"2015","journal-title":"Molecular Cell"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb1590","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1595","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"JAN","key":"10.1016\/j.pharmthera.2020.107579_bb1600","article-title":"The ubiquitin-proteasome system: Potential therapeutic targets for alzheimer's disease and spinal cord injury","volume":"9","author":"Gong","year":"2016","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1605","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1194\/jlr.P065540","article-title":"Associations of human retinal very long-chain polyunsaturated fatty acids with dietary lipid biomarkers","volume":"57","author":"Gorusupudi","year":"2016","journal-title":"Journal of Lipid Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1610","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1615","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1620","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2174\/1871520616666160902101622","article-title":"Second generation proteasome inhibitors in multiple myeloma","volume":"17","author":"Gozzetti","year":"2017","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1625","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"Journal of Cardiac Failure"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb1630","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/chem.201002809","article-title":"Copper(I) and copper(II) inhibit A\u03b2 peptides proteolysis by insulin-degrading enzyme differently: Implications for metallostasis alteration in Alzheimer's disease","volume":"17","author":"Grasso","year":"2011","journal-title":"Chemistry - A European Journal"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1635","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jinorgbio.2012.06.010","article-title":"Metal ions affect insulin-degrading enzyme activity","volume":"117","author":"Grasso","year":"2012","journal-title":"Journal of Inorganic Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccr.2017.06.004","article-title":"The double faced role of copper in A? Homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration","volume":"347","author":"Grasso","year":"2017","journal-title":"Coordination Chemistry Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1645","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/embor.2012.14","article-title":"Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment","volume":"13","author":"Greene","year":"2012","journal-title":"EMBO Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1650","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1074\/jbc.272.1.58","article-title":"Binding of amyloid beta protein to the 20 S proteasome","volume":"272","author":"Gregori","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1655","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1660","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.187.1.97","article-title":"Immunoproteasome assembly: Cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits","volume":"187","author":"Griffin","year":"1998","journal-title":"The Journal of Experimental Medicine"},{"issue":"28","key":"10.1016\/j.pharmthera.2020.107579_bb1665","doi-asserted-by":"crossref","first-page":"24733","DOI":"10.18632\/oncotarget.4619","article-title":"The 26S proteasome is a multifaceted target for anti-cancer therapies","volume":"6","author":"Grigoreva","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb1670","doi-asserted-by":"crossref","first-page":"8970","DOI":"10.1073\/pnas.94.17.8970","article-title":"The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20Sproteasome","volume":"94","author":"Groettrup","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb1675","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nature Structural Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1680","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure (London, England: 1993)"},{"issue":"6624","key":"10.1016\/j.pharmthera.2020.107579_bb1685","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb1690","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1073\/pnas.96.20.10976","article-title":"The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study","volume":"96","author":"Groll","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1695","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1357-2725(02)00390-4","article-title":"Substrate access and processing by the 20S proteasome core particle","volume":"35","author":"Groll","year":"2003","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1700","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1074-5521(02)00144-8","article-title":"Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome","volume":"9","author":"Groll","year":"2002","journal-title":"Chemistry & Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1705","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.freeradbiomed.2011.06.015","article-title":"HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress","volume":"51","author":"Grune","year":"2011","journal-title":"Free Radical Biology & Medicine"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb1710","doi-asserted-by":"crossref","first-page":"15504","DOI":"10.1074\/jbc.271.26.15504","article-title":"Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome","volume":"271","author":"Grune","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb1715","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1073\/pnas.081474898","article-title":"Skp2 is oncogenic and overexpressed in human cancers","volume":"98","author":"Gstaiger","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb1720","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1073\/pnas.95.8.4224","article-title":"Amyloid fibril formation by an SH3 domain","volume":"95","author":"Guijarro","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1725","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.1007\/s12035-016-0260-1","article-title":"A Central Role for Phosphorylated p38\u03b1 in Linking Proteasome Inhibition-Induced Apoptosis and Autophagy","volume":"54","author":"Guo","year":"2017","journal-title":"Molecular Neurobiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1730","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cell.2017.12.030","article-title":"In Situ Structure of Neuronal C9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment","volume":"172","author":"Guo","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1735","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuroscience.2006.11.042","article-title":"Glutamate stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of GluR2","volume":"145","author":"Guo","year":"2007","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1740","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcph.988","volume":"58","author":"Gupta","year":"2018","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb1745","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jcph.719","article-title":"The effect of a high-fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma","volume":"56","author":"Gupta","year":"2016","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1750","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","article-title":"Clinical pharmacology of ixazomib: The first oral proteasome inhibitor","volume":"58","author":"Gupta","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1755","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000431128","article-title":"Retinal anatomy and pathology","volume":"55","author":"Gupta","year":"2016","journal-title":"Developments in Ophthalmology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1760","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fcell.2018.00011","article-title":"Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis","volume":"6","author":"Gupta","year":"2018","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1765","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10637-017-0509-1","article-title":"A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors","volume":"36","author":"Gupta","year":"2018","journal-title":"Investigational New Drugs"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1770","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bcp.12542","article-title":"Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: A population pharmacokinetic analysis","volume":"79","author":"Gupta","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1775","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1074\/jbc.M307050200","article-title":"Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome","volume":"279","author":"Guterman","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"11 II","key":"10.1016\/j.pharmthera.2020.107579_bb1780","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1073\/pnas.78.11.6845","article-title":"Hemin inhibits ATP-dependent ubiquitin-dependent proteolysis: Role of hemin in regulating ubiquitin conjugate degradation","volume":"78","author":"Haas","year":"1981","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1785","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12864-017-3745-z","article-title":"The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model","volume":"18","author":"van Hagen","year":"2017","journal-title":"BMC Genomics"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1790","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005401","article-title":"Redundant roles of Rpn10 and Rpn13 in recognition of ubiquitinated proteins and cellular homeostasis","volume":"11","author":"Hamazaki","year":"2015","journal-title":"PLoS Genetics"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb1795","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1038\/sj.emboj.7601338","article-title":"A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes","volume":"25","author":"Hamazaki","year":"2006","journal-title":"The EMBO Journal"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb1800","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.metabol.2009.04.005","article-title":"Preliminary report: Inhibition of cellular proteasome activity by free fatty acids","volume":"58","author":"Hamel","year":"2009","journal-title":"Metabolism, Clinical and Experimental"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1805","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neuron.2012.04.031","article-title":"Activity-dependent growth of new dendritic spines is regulated by the proteasome","volume":"74","author":"Hamilton","year":"2012","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1810","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: Barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1815","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1038\/ncomms6633","article-title":"Direct cellular delivery of human proteasomes to delay tau aggregation","volume":"5","author":"Han","year":"2014","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb1820","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.7164\/antibiotics.45.1746","article-title":"Epoxomicin, a new antitumor agent of microbial origin","volume":"45","author":"Hanada","year":"1992","journal-title":"The Journal of Antibiotics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1825","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1830","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1835","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cell.2006.07.038","article-title":"Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation","volume":"127","author":"Hanna","year":"2006","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1840","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2007.03.042","article-title":"A ubiquitin stress response induces altered proteasome composition","volume":"129","author":"Hanna","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1845","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.molcel.2014.06.017","article-title":"An inducible chaperone adapts proteasome assembly to stress","volume":"55","author":"Hanssum","year":"2014","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb1850","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/jpet.116.237388","article-title":"TAK-063, a novel phosphodiesterase 10A inhibitor, protects from striatal neurodegeneration and ameliorates behavioral deficits in the R6\/2 mouse model of Huntington's disease","volume":"360","author":"Harada","year":"2017","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1855","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(00)81519-6","article-title":"Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1","volume":"98","author":"Harbour","year":"1999","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb1860","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2018.11","article-title":"Proteostasis in Huntington's disease: Disease mechanisms and therapeutic opportunities","volume":"39","author":"Harding","year":"2018","journal-title":"Acta Pharmacologica Sinica"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1865","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ja.2011.84","article-title":"Proteasome inhibitors mechanism; source for design of newer therapeutic agents","volume":"65","author":"Harer","year":"2012","journal-title":"The Journal of Antibiotics"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb1870","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13696998.2018.1474745","article-title":"Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed\/refractory multiple myeloma","volume":"21","author":"Hari","year":"2018","journal-title":"Journal of Medical Economics"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb1875","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0232-6","article-title":"Oprozomib in patients with newly diagnosed multiple myeloma","volume":"9","author":"Hari","year":"2019","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1880","doi-asserted-by":"crossref","first-page":"106172","DOI":"10.1016\/j.leukres.2019.106172","article-title":"Efficacy and safety results from a phase 1b\/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"83","author":"Hari","year":"2019","journal-title":"Leukemia Research"},{"issue":"30","key":"10.1016\/j.pharmthera.2020.107579_bb1885","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1890","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0005-2736(68)90157-0","article-title":"Release of a macromolecular protein component from human erythrocyte ghosts","volume":"150","author":"Harris","year":"1968","journal-title":"Biochimica et Biophysica Acta"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb1895","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","article-title":"Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: Study NPI-0052-102 final results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb1900","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.str.2014.11.017","article-title":"Crystal structure of the human 20S proteasome in complex with carfilzomib","volume":"23","author":"Harshbarger","year":"2015","journal-title":"Structure (London, England: 1993)"},{"issue":"7356","key":"10.1016\/j.pharmthera.2020.107579_bb1905","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","article-title":"Molecular chaperones in protein folding and proteostasis","volume":"475","author":"Hartl","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1910","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nsmb.1591","article-title":"Converging concepts of protein folding in vitro and in vivo","volume":"16","author":"Hartl","year":"2009","journal-title":"Nature Structural & Molecular Biology"},{"issue":"6630","key":"10.1016\/j.pharmthera.2020.107579_bb1915","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb1920","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.str.2011.12.015","article-title":"The structure of the 26S proteasome subunit Rpn2 reveals its PC repeat domain as a closed toroid of two concentric \u03b1-helical rings","volume":"20","author":"He","year":"2012","journal-title":"Structure (London, England: 1993)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1925","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","article-title":"Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations","volume":"87","author":"Heckman","year":"2018","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2020.107579_bb1930","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00324","article-title":"Perturbations of ubiquitin-proteasome-mediated proteolysis in aging and Alzheimer's disease","volume":"11","author":"Hegde","year":"2019","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"40","key":"10.1016\/j.pharmthera.2020.107579_bb1935","doi-asserted-by":"crossref","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb1940","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.0501711102","article-title":"IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response","volume":"102","author":"Heink","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb1945","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11594410-000000000-00000","article-title":"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma","volume":"50","author":"Hellmann","year":"2011","journal-title":"Clinical Pharmacokinetics"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb1950","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1074\/jbc.AC119.008881","article-title":"Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13","volume":"294","author":"Hemmis","year":"2019","journal-title":"The Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb1955","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.s. Food and Drug Administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1960","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1073\/pnas.77.4.1783","article-title":"Proposed role of ATP in protein breakdown: Conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis","volume":"77","author":"Hershko","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb1965","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1016\/S0021-9258(19)45327-1","article-title":"Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins","volume":"257","author":"Hershko","year":"1982","journal-title":"The Journal of Biological Chemistry"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb1970","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb1975","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb1980","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb1985","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.ejmech.2009.05.019","article-title":"Metals in anticancer therapy: Copper(II) complexes as inhibitors of the 20S proteasome","volume":"44","author":"Hindo","year":"2009","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb1990","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tcb.2014.05.003","article-title":"Proteostasis impairment in protein-misfolding and -aggregation diseases","volume":"24","author":"Hipp","year":"2014","journal-title":"Trends in Cell Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb1995","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molcel.2006.11.015","article-title":"Cooperation of multiple chaperones required for the assembly of mammalian 20S proteasomes","volume":"24","author":"Hirano","year":"2006","journal-title":"Molecular Cell"},{"issue":"7063","key":"10.1016\/j.pharmthera.2020.107579_bb2000","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nature04106","article-title":"A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes","volume":"437","author":"Hirano","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jprot.2015.11.016","article-title":"Biological significance of co- and post-translational modifications of the yeast 26S proteasome","volume":"134","author":"Hirano","year":"2016","journal-title":"Journal of Proteomics"},{"issue":"3\u20135","key":"10.1016\/j.pharmthera.2020.107579_bb2010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijbiomac.2006.03.015","article-title":"Possible tetramerisation of the proteasome maturation factor POMP\/proteassemblin\/hUmp1 and its subcellular localisation","volume":"38","author":"Hoefer","year":"2006","journal-title":"International Journal of Biological Macromolecules"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2015","doi-asserted-by":"crossref","DOI":"10.1038\/srep11028","article-title":"Ubiquitin-specific protease 14 modulates degradation of cellular prion protein","volume":"5","author":"Homma","year":"2015","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2174\/092986611794578332","article-title":"Characterization of the non-fibrillar \u03b1-synuclein oligomers","volume":"18","author":"Hong","year":"2011","journal-title":"Protein and Peptide Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2025","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.4049\/jimmunol.1202749","article-title":"Proteasomal degradation of herpes simplex virus capsids in macrophages releases DNA to the cytosol for recognition by DNA sensors","volume":"190","author":"Horan","year":"2013","journal-title":"Journal of Immunology (Baltimore, MD.: 1950)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2035","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/S0021-9258(17)35950-1","article-title":"Ubiquitin-lysozyme conjugates. Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates","volume":"261","author":"Hough","year":"1986","journal-title":"The Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb2040","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.1016\/S0021-9258(18)47564-3","article-title":"Purification of two high molecular weight proteases from rabbit reticulocyte lysate","volume":"262","author":"Hough","year":"1987","journal-title":"The Journal of Biological Chemistry"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb2045","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1038\/sj.emboj.7600832","article-title":"Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14","volume":"24","author":"Hu","year":"2005","journal-title":"The EMBO Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/vim.2011.0099","article-title":"SARS-CoV regulates immune function-related gene expression in human monocytic cells","volume":"25","author":"Hu","year":"2012","journal-title":"Viral Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb2055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/092986709787581860","article-title":"Proteasome regulators: Activators and inhibitors","volume":"16","author":"Huang","year":"2009","journal-title":"Current Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/13543784.2019.1551359","article-title":"Spotlight on bortezomib: Potential in the treatment of hepatocellular carcinoma","volume":"28","author":"Huang","year":"2019","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb2065","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.febslet.2007.09.031","article-title":"Activation and inhibition of the proteasome by betulinic acid and its derivatives","volume":"581","author":"Huang","year":"2007","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2070","first-page":"1315","article-title":"Sanggenon C decreases tumor cell viability associated with proteasome inhibition","volume":"3","author":"Huang","year":"2011","journal-title":"Frontiers in Bioscience (Elite Edition)"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb2075","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: A review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncology (London, England)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10900","article-title":"A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome","volume":"7","author":"Huber","year":"2016","journal-title":"Nature Communications"},{"issue":"7194","key":"10.1016\/j.pharmthera.2020.107579_bb2085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature06926","article-title":"Proteasome subunit Rpn13 is a novel ubiquitin receptor","volume":"453","author":"Husnjak","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2090","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/j.1471-4159.2010.06688.x","article-title":"Immunoproteasome deficiency alters retinal proteasome's response to stress","volume":"113","author":"Hussong","year":"2010","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2095","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1167\/iovs.10-6032","article-title":"A novel role for the immunoproteasome in retinal function","volume":"52","author":"Hussong","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb2100","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1093\/hmg\/ddu317","article-title":"Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: Involvement of the proteasome and ER stress-activated kinase IRE1\u03b1","volume":"23","author":"Hyrskyluoto","year":"2014","journal-title":"Human Molecular Genetics"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb2105","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1093\/emboj\/cdg349","article-title":"The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome","volume":"22","author":"Imai","year":"2003","journal-title":"The EMBO Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","article-title":"A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"Investigational New Drugs"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb2115","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1093\/hmg\/ddq288","article-title":"Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics","volume":"19","author":"Irrcher","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.molcel.2010.05.001","article-title":"Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome","volume":"38","author":"Isasa","year":"2010","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.wno.0000204645.56873.26","article-title":"Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease","volume":"26","author":"Iseri","year":"2006","journal-title":"Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2135","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pediatrneurol.2010.02.018","article-title":"Ocular MECP2 protein expression in patients with and without Rett syndrome","volume":"43","author":"Jain","year":"2010","journal-title":"Pediatric Neurology"},{"issue":"42","key":"10.1016\/j.pharmthera.2020.107579_bb2145","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9\u2013based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2020.107579_bb2150","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/jco.2013.31.15_suppl.8543","article-title":"Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up","volume":"31","author":"Jakubowiak","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb2155","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s12035-012-8318-1","article-title":"Defective autophagy in Parkinson's disease: Role of oxidative stress","volume":"46","author":"Janda","year":"2012","journal-title":"Molecular Neurobiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15430\/JCP.2018.23.4.153","article-title":"Regulation of Protein Degradation by Proteasomes in Cancer","volume":"23","author":"Jang","year":"2018","journal-title":"Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2170","article-title":"CaMKII, but not protein kinase A, regulates Rpt6 phosphorylation and proteasome activity during the formation of long-term memories","volume":"7","author":"Jarome","year":"2013","journal-title":"Frontiers in Behavioral Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2175","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1582-4934.2011.01507.x","article-title":"Interaction between pathogenic proteins in neurodegenerative disorders","volume":"16","author":"Jellinger","year":"2012","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2180","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/brv.12419","article-title":"Substrate receptors of proteasomes","volume":"93","author":"Jiang","year":"2018","journal-title":"Biological Reviews of the Cambridge Philosophical Society"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb2185","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.477","article-title":"Docosahexaenoic acid induces the degradation of HPV E6\/E7 oncoproteins by activating the ubiquitin-proteasome system","volume":"5","author":"Jing","year":"2014","journal-title":"Cell Death & Disease"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb2190","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1093\/hmg\/ddv082","article-title":"Mutated myocilin and heterozygous Sod2 deficiency act synergistically in a mouse model of open-angle glaucoma","volume":"24","author":"Joe","year":"2015","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2195","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-14-0005","article-title":"The ubiquitin-proteasome system: Opportunities for therapeutic intervention in solid tumors","volume":"22","author":"Johnson","year":"2015","journal-title":"Endocrine-Related Cancer"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb2200","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24152841","article-title":"Proteasome activation to combat proteotoxicity","volume":"24","author":"Jones","year":"2019","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb2205","doi-asserted-by":"crossref","first-page":"23851","DOI":"10.1074\/jbc.C400111200","article-title":"Proteasomal degradation of RPN4 via two distinct mechanisms, ubiquitin-dependent and -independent","volume":"279","author":"Ju","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2210","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-19538-0","article-title":"Dynamic recruitment of ubiquitin to mutant huntingtin inclusion bodies","volume":"8","author":"Juenemann","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2215","first-page":"8","article-title":"Detection of ubiquitinated huntingtin species in intracellular aggregates","author":"Juenemann","year":"2015","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mcn.2017.02.006","article-title":"Parkin promotes proteasomal degradation of synaptotagmin IV by accelerating polyubiquitination","volume":"80","author":"Kabayama","year":"2017","journal-title":"Molecular and Cellular Neurosciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217945","article-title":"Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats","volume":"14","author":"Kageyama","year":"2019","journal-title":"PLoS One"},{"issue":"7471","key":"10.1016\/j.pharmthera.2020.107579_bb2230","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"6106","key":"10.1016\/j.pharmthera.2020.107579_bb2235","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","article-title":"Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect","volume":"103","author":"Kaplan","year":"2017","journal-title":"Free Radical Biology & Medicine"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb2245","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","article-title":"Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis","volume":"70","author":"Kapuria","year":"2010","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2250","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nature Reviews. Cancer"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb2255","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking inflammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nature Reviews. Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb2260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143038","article-title":"Interplay between structure and charge as a key to allosteric modulation of human 20S proteasome by the basic fragment of HIV-1 tat protein","volume":"10","author":"Karpowicz","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb2265","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Advances"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2270","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/rej.2006.0513","article-title":"The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts","volume":"10","author":"Katsiki","year":"2007","journal-title":"Rejuvenation Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejphar.2018.05.015","article-title":"Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP\/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats","volume":"832","author":"Kaundal","year":"2018","journal-title":"European Journal of Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb2280","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/icb.2016.50","article-title":"Emerging role of immunoproteasomes in pathophysiology","volume":"94","author":"Kaur","year":"2016","journal-title":"Immunology & Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1471-4159.2003.01642.x","article-title":"Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease","volume":"85","author":"Keck","year":"2003","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2290","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1471-4159.2000.0750436.x","article-title":"Impaired proteasome function in Alzheimer's disease","volume":"75","author":"Keller","year":"2000","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12960","article-title":"Structure of ubiquitylated-Rpn10 provides insight into its autoregulation mechanism","volume":"7","author":"Keren-Kaplan","year":"2016","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/thoraxjnl-2012-202536","article-title":"Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury","volume":"68","author":"Kerrin","year":"2013","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb2305","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1128\/MCB.26.8.2999-3007.2006","article-title":"Proteasome activator PA200 is required for normal spermatogenesis","volume":"26","author":"Khor","year":"2006","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2310","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/978-1-4419-7002-2_11","article-title":"Protein homeostasis in models of aging and age-related conformational disease","volume":"694","author":"Kikis","year":"2010","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2315","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1039\/c3np20126k","article-title":"From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes","volume":"30","author":"Kim","year":"2013","journal-title":"Natural Product Reports"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb2320","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1074\/jbc.M116.763128","article-title":"The deubiquitinating enzyme Usp14 allosterically inhibits multiple proteasomal activities and ubiquitin-independent proteolysis","volume":"292","author":"Kim","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2325","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.cdd.4401877","article-title":"NF-kappaB and IKK as therapeutic targets in cancer","volume":"13","author":"Kim","year":"2006","journal-title":"Cell Death and Differentiation"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb2330","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1128\/MCB.21.22.7707-7713.2001","article-title":"Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-causing mutations are gain of function","volume":"21","author":"Kim","year":"2001","journal-title":"Molecular and Cellular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2335","doi-asserted-by":"crossref","first-page":"739","DOI":"10.15252\/embj.201490736","article-title":"Reprogramming of human cancer cells to pluripotency for models of cancer progression","volume":"34","author":"Kim","year":"2015","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2340","doi-asserted-by":"crossref","first-page":"541984","DOI":"10.1155\/2015\/541984","article-title":"New insights into the function of the immunoproteasome in immune and nonimmune cells","volume":"2015","author":"Kimura","year":"2015","journal-title":"Journal of Immunology Research"},{"issue":"5293","key":"10.1016\/j.pharmthera.2020.107579_bb2345","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.274.5293.1652","article-title":"How proteolysis drives the cell cycle","volume":"274","author":"King","year":"1996","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2350","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bbadis.2017.03.017","article-title":"Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer's disease","volume":"1863","author":"Kiprowska","year":"2017","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2355","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-biophys-083012-130417","article-title":"Structural biology of the proteasome","volume":"42","author":"Kish-Trier","year":"2013","journal-title":"Annual Review of Biophysics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2360","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Molecular Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb2365","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: From research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chemistry & Biology"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb2370","doi-asserted-by":"crossref","first-page":"22260","DOI":"10.1074\/jbc.M112360200","article-title":"Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings","volume":"277","author":"Kisselev","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb2375","doi-asserted-by":"crossref","first-page":"14831","DOI":"10.1074\/jbc.275.20.14831","article-title":"Why does threonine, and not serine, function as the active site nucleophile in proteasomes?","volume":"275","author":"Kisselev","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: An expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chemistry & Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1083\/jcb.201709072","article-title":"Pathways of cellular proteostasis in aging and disease","volume":"217","author":"Klaips","year":"2018","journal-title":"The Journal of Cell Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006098","article-title":"C-terminal tyrosine residue modifications modulate the protective phosphorylation of serine 129 of \u03b1-synuclein in a yeast model of Parkinson's disease","volume":"12","author":"Kleinknecht","year":"2016","journal-title":"PLoS Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2395","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1357-2725(96)00143-4","article-title":"Purification and characterization of proteasome from ostrich liver","volume":"29","author":"Klinkradt","year":"1997","journal-title":"International Journal of Biochemistry & Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tibs.2013.10.004","article-title":"The unique functions of tissue-specific proteasomes","volume":"39","author":"Kniepert","year":"2014","journal-title":"Trends in Biochemical Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2405","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1523\/JNEUROSCI.0429-08.2009","article-title":"The COP9 signalosome is required for light-dependent timeless degradation and Drosophila clock resetting","volume":"29","author":"Knowles","year":"2009","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2020.107579_bb2410","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0300-9084(01)01242-1","article-title":"The substrate translocation channel of the proteasome","volume":"83","author":"K\u00f6hler","year":"2001","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2415","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1097-2765(01)00274-X","article-title":"The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release","volume":"7","author":"K\u00f6hler","year":"2001","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2420","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.isci.2019.01.018","article-title":"Alzheimer A\u03b2 assemblies accumulate in excitatory neurons upon proteasome inhibition and kill nearby NAK\u03b13 neurons by secretion","volume":"13","author":"Komura","year":"2019","journal-title":"IScience"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2425","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2430","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2019.00048","article-title":"Regulation of proteasome activity by (post-)transcriptional mechanisms","volume":"6","author":"Kors","year":"2019","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2435","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1091\/mbc.e07-10-1040","article-title":"Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome","volume":"19","author":"Koulich","year":"2008","journal-title":"Molecular Biology of the Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2440","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2445","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1038\/s41467-018-05320-3","article-title":"The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington's disease patients","volume":"9","author":"Koyuncu","year":"2018","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-15708-8","article-title":"Two-step process for disassembly mechanism of proteasome \u03b17 homo-tetradecamer by \u03b16 revealed by high-speed atomic force microscopy","volume":"7","author":"Kozai","year":"2017","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2455","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nature Genetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb2460","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2014.109421","article-title":"The novel \u03b22-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells","volume":"100","author":"Kraus","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2465","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.molcel.2009.01.023","article-title":"Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor","volume":"33","author":"Kravtsova-Ivantsiv","year":"2009","journal-title":"Molecular Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009367","article-title":"Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1","volume":"5","author":"Krebiehl","year":"2010","journal-title":"PLoS One"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2020.107579_bb2475","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0300-9084(01)01241-X","article-title":"20S proteasome biogenesis","volume":"83","author":"Kr\u00fcger","year":"2001","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2480","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107579_bb2485","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1134\/S0006297919140104","article-title":"Proteasome: A nanomachinery of creative destruction","volume":"84","author":"Kudriaeva","year":"2019","journal-title":"Biochemistry. Biokhimiia"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2490","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1096\/fj.201802237R","article-title":"Charge-mediated proteasome targeting","volume":"33","author":"Kudriaeva","year":"2019","journal-title":"FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2495","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1074\/mcp.O116.065136","article-title":"Loss-less nano-fractionator for high sensitivity, high coverage proteomics","volume":"16","author":"Kulak","year":"2017","journal-title":"Molecular & Cellular Proteomics: MCP"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb2500","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb2505","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"The Lancet. Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb2510","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb2515","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","article-title":"Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2520","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer Journal"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2020.107579_bb2530","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-017-3239-y","article-title":"Alpha-synuclein aggregation, ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: Resemblance to sporadic Parkinson's disease","volume":"444","author":"Kumar","year":"2018","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb2535","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2540","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbamcr.2013.03.008","article-title":"Assembly of the 20S proteasome","volume":"1843","author":"Kunjappu","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2545","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2550","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/pro.3153","article-title":"Crystal structure of human proteasome assembly chaperone PAC4 involved in proteasome formation","volume":"26","author":"Kurimoto","year":"2017","journal-title":"Protein Science: A Publication of the Protein Society"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2555","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1073\/pnas.1417423112","article-title":"STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease","volume":"112","author":"Kurup","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2560","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nsmb.1389","article-title":"A multimeric assembly factor controls the formation of alternative 20S proteasomes","volume":"15","author":"Kusmierczyk","year":"2008","journal-title":"Nature Structural & Molecular Biology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb2565","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington's disease: Underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2570","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-biochem-060614-033955","article-title":"The biology of proteostasis in aging and disease","volume":"84","author":"Labbadia","year":"2015","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2575","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.phrs.2018.08.023","article-title":"Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors","volume":"136","author":"Lacal","year":"2018","journal-title":"Pharmacological Research"},{"issue":"6618","key":"10.1016\/j.pharmthera.2020.107579_bb2580","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/385737a0","article-title":"Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome","volume":"385","author":"Lam","year":"1997","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb2585","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2590","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10534-016-9942-4","article-title":"The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms","volume":"29","author":"Lan","year":"2016","journal-title":"BioMetals"},{"issue":"7384","key":"10.1016\/j.pharmthera.2020.107579_bb2595","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature10774","article-title":"Complete subunit architecture of the proteasome regulatory particle","volume":"482","author":"Lander","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2600","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drup.2006.11.001","article-title":"The proteasome as a potential target for novel anticancer drugs and chemosensitizers","volume":"9","author":"Landis-Piwowar","year":"2006","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb2605","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107579_bb2610","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/S1353-8020(13)70038-5","article-title":"Role of iron in UPS impairment model of Parkinson's disease","volume":"20","author":"Le","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2615","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.visres.2017.05.005","article-title":"VEGF production and signaling in M\u00fcller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases","volume":"139","author":"Le","year":"2017","journal-title":"Vision Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2620","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.molcel.2007.06.025","article-title":"20S proteasome assembly is orchestrated by two distinct pairs of chaperones in yeast and in mammals","volume":"27","author":"Le Tallec","year":"2007","journal-title":"Molecular Cell"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb2625","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1111\/j.1742-4658.2007.05947.x","article-title":"Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus","volume":"274","author":"Le","year":"2007","journal-title":"The FEBS Journal"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb2630","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb2635","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1681\/ASN.2006010083","article-title":"Protein degradation by the ubiquitin-proteasome pathway in normal and disease states","volume":"17","author":"Lecker","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4994","key":"10.1016\/j.pharmthera.2020.107579_bb2640","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1899488","article-title":"A68: a major subunit of paired helical filaments and derivatized forms of normal Tau","volume":"251","author":"Lee","year":"1991","journal-title":"Science (New York, N.Y.)"},{"issue":"42","key":"10.1016\/j.pharmthera.2020.107579_bb2645","doi-asserted-by":"crossref","first-page":"36641","DOI":"10.1074\/jbc.M111.280875","article-title":"Loss of Rpt5 protein interactions with the core particle and Nas2 protein causes the formation of faulty proteasomes that are inhibited by Ecm29 protein","volume":"286","author":"Lee","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb2650","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies","volume":"17","author":"Lee","year":"2011","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2655","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1038\/srep11559","article-title":"iRhom1 regulates proteasome activity via PAC1\/2 under ER stress","volume":"5","author":"Lee","year":"2015","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2660","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cbi.2013.04.006","article-title":"Structural requirements within protoporphyrin IX in the inhibition of heat shock protein 90","volume":"204","author":"Lee","year":"2013","journal-title":"Chemico-Biological Interactions"},{"issue":"7312","key":"10.1016\/j.pharmthera.2020.107579_bb2665","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2670","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","article-title":"Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system","volume":"105","author":"Lee","year":"2013","journal-title":"Progress in Neurobiology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb2675","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2174\/0929867323666160510122624","article-title":"Skp2 Inhibitors: Novel Anticancer Strategies","volume":"23","author":"Lee","year":"2016","journal-title":"Current Medicinal Chemistry"},{"issue":"7599","key":"10.1016\/j.pharmthera.2020.107579_bb2680","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nature17433","article-title":"USP14 deubiquitinates proteasome-bound substrates that are ubiquitinated at multiple sites","volume":"532","author":"Lee","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2685","first-page":"1","article-title":"H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth","volume":"9","author":"Lee","year":"2019","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2690","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.chembiol.2017.05.010","article-title":"Proteasome activation by small molecules","volume":"24","author":"Leestemaker","year":"2017","journal-title":"Cell Chemical Biology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2695","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ddtec.2017.11.006","article-title":"Tools to investigate the ubiquitin proteasome system","volume":"26","author":"Leestemaker","year":"2017","journal-title":"Drug Discovery Today: Technologies"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2700","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(02)00638-X","article-title":"Multiple associated proteins regulate proteasome structure and function","volume":"10","author":"Leggett","year":"2002","journal-title":"Molecular Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2705","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.molcel.2010.06.016","article-title":"Ecm29 fulfils quality control functions in proteasome assembly","volume":"38","author":"Lehmann","year":"2010","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2710","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","article-title":"Role of proteasome inhibitors in relapsed and\/or refractory multiple myeloma","volume":"19","author":"Leleu","year":"2019","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2715","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25134","article-title":"Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","author":"Leleu","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2720","first-page":"273","article-title":"Review. Clinical pharmacokinetics of bortezomib","volume":"21","author":"Lev\u00eaque","year":"2007","journal-title":"In Vivo (Athens, Greece)"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2725","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.14113","article-title":"Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients","volume":"174","author":"Levin","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2730","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.molcel.2007.05.028","article-title":"Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway","volume":"26","author":"Li","year":"2007","journal-title":"Molecular Cell"},{"issue":"50","key":"10.1016\/j.pharmthera.2020.107579_bb2735","doi-asserted-by":"crossref","first-page":"29854","DOI":"10.1074\/jbc.M115.664953","article-title":"The nuclear factor (erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myeloma","volume":"290","author":"Li","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2740","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2009.05.009","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-na\u00efve patients with advanced stage non-small cell lung cancer (NSCLC)","volume":"68","author":"Li","year":"2010","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2745","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ebiom.2018.11.047","article-title":"A new gold(I) complex-au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth","volume":"39","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2750","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2018.05.018","article-title":"PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation","volume":"430","author":"Li","year":"2018","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2755","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2011.09.020","article-title":"Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation","volume":"314","author":"Li","year":"2012","journal-title":"Cancer Letters"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2760","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4161\/cc.23882","article-title":"Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest","volume":"12","author":"Li","year":"2013","journal-title":"Cell Cycle (Georgetown, Texas)"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2765","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1158\/1535-7163.MCT-07-2444","article-title":"Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells","volume":"7","author":"Li","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"issue":"6965","key":"10.1016\/j.pharmthera.2020.107579_bb2770","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2775","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1096\/fj.10-160895","article-title":"Enhancement of proteasome function by PA28\u03b1 overexpression protects against oxidative stress","volume":"25","author":"Li","year":"2011","journal-title":"The FASEB Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2780","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.virol.2007.04.035","article-title":"The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2","volume":"367","author":"Li","year":"2007","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb2785","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1073\/pnas.1612922114","article-title":"Nucleotide-dependent switch in proteasome assembly mediated by the Nas6 chaperone","volume":"114","author":"Li","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2790","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3802\/jgo.2016.27.e43","article-title":"Advances in diagnosis and treatment of metastatic cervical cancer","volume":"27","author":"Li","year":"2016","journal-title":"Journal of Gynecologic Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb2795","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1002\/pmic.201200225","article-title":"Correlation between TGF-\u03b21 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease","volume":"12","author":"Li","year":"2012","journal-title":"Proteomics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb2800","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/tx400032n","article-title":"Boronic acid-containing proteasome inhibitors: Alert to potential pharmaceutical bioactivation","volume":"26","author":"Li","year":"2013","journal-title":"Chemical Research in Toxicology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb2805","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1021\/acs.analchem.6b00032","article-title":"Binding states of protein-metal complexes in cells","volume":"88","author":"Li","year":"2016","journal-title":"Analytical Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb2810","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/1535-7163.MCT-09-0327","article-title":"Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death","volume":"8","author":"Li","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb2815","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/cdd.2008.134","article-title":"WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis","volume":"15","author":"Li","year":"2008","journal-title":"Cell Death and Differentiation"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2820","doi-asserted-by":"crossref","first-page":"e2585","DOI":"10.1038\/cddis.2016.477","article-title":"Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor","volume":"8","author":"Liao","year":"2017","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2825","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.81","article-title":"The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity","volume":"2","author":"Lichtenberg","year":"2011","journal-title":"Cell Death & Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004987","article-title":"Proteotoxic stress induces phosphorylation of p62\/SQSTM1 by ULK1 to regulate selective autophagic clearance of protein aggregates","volume":"11","author":"Lim","year":"2015","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2835","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00628","article-title":"A sentinel in the crosstalk between the nervous and immune system: The (Immuno)-proteasome","volume":"10","author":"Limanaqi","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb2840","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/MCB.01434-12","article-title":"Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease","volume":"33","author":"Lin","year":"2013","journal-title":"Molecular and Cellular Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb2845","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.oraloncology.2012.01.012","article-title":"CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells","volume":"48","author":"Lin","year":"2012","journal-title":"Oral Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2850","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainres.2016.03.027","article-title":"Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin","volume":"1643","author":"Lin","year":"2016","journal-title":"Brain Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb2855","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","article-title":"Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein","volume":"64","author":"Lin","year":"2009","journal-title":"Neuron"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb2860","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJMp2002125","article-title":"Defining the epidemiology of SARS-Cov-2 \u2014 Studies needed","volume":"382","author":"Lipsitch","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2865","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-017-0915-5","article-title":"MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis","volume":"14","author":"Lipski","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2870","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2014.06.013","article-title":"Accessory proteins of SARS-CoV and other coronaviruses","volume":"109","author":"Liu","year":"2014","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2875","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10571-013-0022-9","article-title":"The proteasome function reporter GFPu accumulates in young brains of the APPswe\/PS1dE9 Alzheimer's disease mouse models","volume":"34","author":"Liu","year":"2014","journal-title":"Cellular and Molecular Neurobiology"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb2880","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.18632\/oncotarget.2113","article-title":"Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2885","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.molcel.2006.08.025","article-title":"ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome","volume":"24","author":"Liu","year":"2006","journal-title":"Molecular Cell"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb2890","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1093\/hmg\/ddx327","article-title":"FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells","volume":"26","author":"Liu","year":"2017","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2895","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-018-04117-8","article-title":"Increased proteasomal activity supports photoreceptor survival in inherited retinal degeneration","volume":"9","author":"Lobanova","year":"2018","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2900","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm0297-231","article-title":"Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas","volume":"3","author":"Loda","year":"1997","journal-title":"Nature Medicine"},{"issue":"52","key":"10.1016\/j.pharmthera.2020.107579_bb2905","first-page":"E7176","article-title":"cAMP-induced phosphorylation of 26S proteasomes on Rpn6\/PSMD11 enhances their activity and the degradation of misfolded proteins","volume":"112","author":"Lokireddy","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb2910","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/IAE.0b013e3182899326","article-title":"Analysis of retinal capillaries in patients with type 1 diabetes and nonproliferative diabetic retinopathy using adaptive optics imaging","volume":"33","author":"Lombardo","year":"2013","journal-title":"Retina (Philadelphia, PA.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2915","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrneurol.2012.227","article-title":"The retina as a window to the brain-from eye research to CNS disorders","volume":"9","author":"London","year":"2013","journal-title":"Nature Reviews. Neurology"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb2920","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.1074\/jbc.272.20.12893","article-title":"p53-dependent induction of apoptosis by proteasome inhibitors","volume":"272","author":"Lopes","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb2925","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0014-4886(02)00060-2","article-title":"Relationship between beta-amyloid degradation and the 26S proteasome in neural cells","volume":"180","author":"Lopez Salon","year":"2003","journal-title":"Experimental Neurology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb2930","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1046\/j.0953-816x.2001.01806.x","article-title":"The ubiquitin-proteasome cascade is required for mammalian long-term memory formation","volume":"14","author":"Lopez-Salon","year":"2001","journal-title":"The European Journal of Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb2935","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-11-2873","article-title":"Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432","volume":"18","author":"LoRusso","year":"2012","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2940","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-510X(98)00092-6","article-title":"Copper, iron and zinc in Alzheimer's disease senile plaques","volume":"158","author":"Lovell","year":"1998","journal-title":"Journal of the Neurological Sciences"},{"issue":"5210","key":"10.1016\/j.pharmthera.2020.107579_bb2945","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution","volume":"268","author":"L\u00f6we","year":"1995","journal-title":"Science (New York, N.Y.)"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb2950","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1074\/mcp.M800064-MCP200","article-title":"Revealing the dynamics of the 20 S proteasome phosphoproteome: A combined CID and electron transfer dissociation approach","volume":"7","author":"Lu","year":"2008","journal-title":"Molecular & Cellular Proteomics: MCP"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2955","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030751","article-title":"Effect of Bortezomib on Global Gene Expression in PC12-Derived Nerve Cells","volume":"21","author":"\u0141uczkowska","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2960","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer Journal"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb2965","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1007\/s12035-018-0900-8","article-title":"Herp promotes degradation of mutant Huntingtin: Involvement of the proteasome and molecular chaperones","volume":"55","author":"Luo","year":"2018","journal-title":"Molecular Neurobiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb2970","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4103\/1673-5374.264473","article-title":"20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients","volume":"15","author":"Lv","year":"2020","journal-title":"Neural Regeneration Research"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb2975","doi-asserted-by":"crossref","first-page":"12419","DOI":"10.1128\/JVI.01219-10","article-title":"Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome","volume":"84","author":"Ma","year":"2010","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb2980","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.omto.2019.12.013","article-title":"Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency","volume":"16","author":"Ma","year":"2020","journal-title":"Molecular Therapy - Oncolytics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2985","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb2990","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.cdd.4400801","article-title":"p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells","volume":"8","author":"MacLaren","year":"2001","journal-title":"Cell Death and Differentiation"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb2995","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"C-Abl phosphorylates \u03b1-synuclein and regulates its degradation: Implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson's disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Human Molecular Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3000","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2011.04.010","article-title":"ClpX(P) generates mechanical force to unfold and translocate its protein substrates","volume":"145","author":"Maillard","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3005","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1073\/pnas.1817752116","article-title":"Cryo-EM structures of the archaeal PAN-proteasome reveal an around-the-ring ATPase cycle","volume":"116","author":"Majumder","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3015","doi-asserted-by":"crossref","first-page":"18953","DOI":"10.1038\/srep18953","article-title":"Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo","volume":"6","author":"Manton","year":"2016","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/cr8004857","article-title":"Catalytic mechanism and assembly of the proteasome","volume":"109","author":"Marques","year":"2009","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fmolb.2019.00040","article-title":"Dynamic regulation of the 26S proteasome: From synthesis to degradation","volume":"6","author":"Marshall","year":"2019","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb3030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.1503","article-title":"Pore loops of the AAA+ ClpX machine grip substrates to drive translocation and unfolding","volume":"15","author":"Martin","year":"2008","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3035","doi-asserted-by":"crossref","unstructured":"Maryon, E. B., Molloy, S. A., Zimnicka, A. M., & Kaplan, J. H. (2007). Copper entry into human cells: Progress and unanswered questions. BioMetals, 20(3\u20134), 355\u2013364. https:\/\/doi.org\/10.1007\/s10534-006-9066-3.","DOI":"10.1007\/s10534-006-9066-3"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/187152009787313837","article-title":"Copper complexes as anticancer agents","volume":"9","author":"Marzano","year":"2009","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb3045","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-09-0913","article-title":"Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells","volume":"69","author":"Masamha","year":"2009","journal-title":"Cancer Research"},{"issue":"10218","key":"10.1016\/j.pharmthera.2020.107579_bb3050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3055","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3060","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb3065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"Mateos","year":"2017","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb3070","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3075","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1099\/vir.0.2008\/003962-0","article-title":"Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2","volume":"89","author":"Mathewson","year":"2008","journal-title":"The Journal of General Virology"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2020.107579_bb3080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BST0380029","article-title":"Chaperone-assisted assembly of the proteasome core particle","volume":"38","author":"Matias","year":"2010","journal-title":"Biochemical Society Transactions"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mrd.1080290215","article-title":"Proteasome (multicatalytic proteinase) of sea urchin sperm and its possible participation in the acrosome reaction","volume":"29","author":"Matsumura","year":"1991","journal-title":"Molecular Reproduction and Development"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exer.2014.05.011","article-title":"Neuroprotection by rat M\u00fcller glia against high glucose-induced neurodegeneration through a mechanism involving ERK1\/2 activation","volume":"125","author":"Matteucci","year":"2014","journal-title":"Experimental Eye Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrn1886","article-title":"Aging and neuronal vulnerabilitys","volume":"7","author":"Mattson","year":"2006","journal-title":"Nature Review. Neuroscience"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nsmb.2616","article-title":"Conformational switching of the 26S proteasome enables substrate degradation","volume":"20","author":"Matyskiela","year":"2013","journal-title":"Nature Structural & Molecular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3105","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1073\/pnas.91.9.3564","article-title":"Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells","volume":"91","author":"Mayaux","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40263-019-00657-9","article-title":"Emerging developments in targeting proteotoxicity in neurodegenerative diseases","volume":"33","author":"McAlary","year":"2019","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00401-015-1508-y","article-title":"Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system","volume":"131","author":"McKinnon","year":"2016","journal-title":"Acta Neuropathologica"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb3120","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1089\/ars.2013.5802","article-title":"The ubiquitin-proteasome system in neurodegeneration","volume":"21","author":"McKinnon","year":"2014","journal-title":"Antioxidants & Redox Signaling"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1471-4159.2002.00821.x","article-title":"Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures","volume":"81","author":"McNaught","year":"2002","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","article-title":"Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease","volume":"56","author":"McNaught","year":"2004","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3135","first-page":"11","article-title":"Retinal antigen-specific regulatory T cells protect against spontaneous and induced autoimmunity and require local dendritic cells","author":"McPherson","year":"2014","journal-title":"Journal of Neuroinflammation"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb3140","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3145","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1038\/cddis.2012.70","article-title":"Coordination between proteasome impairment and caspase activation leading to TAU pathology: Neuroprotection by cAMP","volume":"3","author":"Metcalfe","year":"2012","journal-title":"Cell Death & Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/carcin\/bgq242","article-title":"Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells","volume":"32","author":"Mi","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jinorgbio.2014.08.001","article-title":"Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities","volume":"141","author":"Micale","year":"2014","journal-title":"Journal of Inorganic Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3160","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12325-016-0285-x","article-title":"Differential protein expression profiles in glaucomatous trabecular meshwork: An evaluation study on a small primary open angle glaucoma population","volume":"33","author":"Micera","year":"2016","journal-title":"Advances in Therapy"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb3165","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.arr.2014.09.005","article-title":"The measurement of protein synthesis for assessing proteostasis in studies of slowed aging","volume":"18","author":"Miller","year":"2014","journal-title":"Ageing Research Reviews"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb3175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008342","article-title":"The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor","volume":"4","author":"Minakshi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3180","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1038\/srep33742","article-title":"CCT2 mutations evoke Leber congenital amaurosis due to chaperone complex instability","volume":"6","author":"Minegishi","year":"2016","journal-title":"Scientific Reports"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb3185","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJM199612193352507","article-title":"Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway","volume":"335","author":"Mitch","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3190","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3195","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2007.05.003","article-title":"PCNA, the maestro of the replication fork","volume":"129","author":"Moldovan","year":"2007","journal-title":"Cell"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2020.107579_bb3200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-1119(99)00487-4","article-title":"MDM2--master regulator of the p53 tumor suppressor protein","volume":"242","author":"Momand","year":"2000","journal-title":"Gene"},{"issue":"10192","key":"10.1016\/j.pharmthera.2020.107579_bb3205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb3210","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood-2015-02-626168","article-title":"Phase 1\/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb3215","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","article-title":"Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m2 vs. twice-weekly 27 mg\/m2 carfilzomib (randomized A.R.R.O.W. study)","volume":"33","author":"Moreau","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb3220","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3225","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): Interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"The Lancet. Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3235","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.2945","article-title":"Once-weekly (70 mg\/m2) vs twice-weekly (56 mg\/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials","author":"Moreau","year":"2020","journal-title":"Cancer Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3240","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/jdv.13898","article-title":"KLICK syndrome: Recognizable phenotype and hot-spot POMP mutation","volume":"31","author":"Morice-Picard","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb3245","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1101\/gad.1657108","article-title":"Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging","volume":"22","author":"Morimoto","year":"2008","journal-title":"Genes & Development"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02785387","article-title":"The effect of aging on the mineral status of female mice","volume":"42","author":"Morita","year":"1994","journal-title":"Biological Trace Element Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3389\/fonc.2019.00761","article-title":"Proteasomes and several aspects of their heterogeneity relevant to cancer","volume":"9","author":"Morozov","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb3260","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/nn.4067","article-title":"Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice","volume":"18","author":"Morris","year":"2015","journal-title":"Nature Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb3265","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2174\/1568009618666180308105048","article-title":"Noxa: Role in Cancer Pathogenesis and Treatment","volume":"18","author":"Morsi","year":"2018","journal-title":"Current Cancer Drug Targets"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb3270","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1073\/pnas.0501034102","article-title":"Recruitment of DNA methyltransferase I to DNA repair sites","volume":"102","author":"Mortusewicz","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3275","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1038\/ncomms7609","article-title":"The Parkinson's-associated protein DJ-1 regulates the 20S proteasome","volume":"6","author":"Moscovitz","year":"2015","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3280","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CAD.0b013e3283357c62","article-title":"Betulinic acid, a natural compound with potent anticancer effects","volume":"21","author":"Mullauer","year":"2010","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3285","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3164\/jcbn.12-126","article-title":"Modulation of protein quality control systems by food phytochemicals","volume":"52","author":"Murakami","year":"2013","journal-title":"Journal of Clinical Biochemistry and Nutrition"},{"issue":"6404","key":"10.1016\/j.pharmthera.2020.107579_bb3290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/360597a0","article-title":"Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination","volume":"360","author":"Murakami","year":"1992","journal-title":"Nature"},{"issue":"5829","key":"10.1016\/j.pharmthera.2020.107579_bb3295","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8+ T cell development by thymus-specific proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science (New York, N.Y.)"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3300","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: Functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nature Immunology"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb3305","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1093\/emboj\/20.21.5898","article-title":"Immunoproteasome assembly and antigen presentation in mice lacking both PA28\u03b1 and PA28\u03b2","volume":"20","author":"Murata","year":"2001","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3310","first-page":"217","article-title":"Spotlight on ixazomib: Potential in the treatment of multiple myeloma","volume":"10","author":"Muz","year":"2016","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3315","doi-asserted-by":"crossref","unstructured":"Myeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V, Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016). Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nature Medicine, 22(1), 46\u201353. https:\/\/doi.org\/10.1038\/nm.4011.","DOI":"10.1038\/nm.4011"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3320","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molmed.2017.11.006","article-title":"Targeting the 26S proteasome to protect against proteotoxic diseases","volume":"24","author":"Myeku","year":"2018","journal-title":"Trends in Molecular Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3325","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1097-2765(01)00188-5","article-title":"Lack of proteasome active site allostery as revealed by subunit-specific inhibitors","volume":"7","author":"Myung","year":"2001","journal-title":"Molecular Cell"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb3330","first-page":"2344","article-title":"Light exposure induces ubiquitin conjugation and degradation activities in the rat retina","volume":"38","author":"Naash","year":"1997","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3335","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.micron.2012.01.011","article-title":"Ultrastructure of the human retina in aging and various pathological states","volume":"43","author":"Nag","year":"2012","journal-title":"Micron (Oxford, England: 1993)"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3340","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrc1588","article-title":"Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs","volume":"5","author":"Nakanishi","year":"2005","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3345","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejmech.2018.08.099","article-title":"Role of p53 circuitry in tumorigenesis: A brief review","volume":"158","author":"Niazi","year":"2018","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3355","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3360","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2010.176","article-title":"Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: Implications for Alzheimer's disease","volume":"18","author":"Nijholt","year":"2011","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3365","doi-asserted-by":"crossref","first-page":"146641","DOI":"10.1016\/j.brainres.2019.146641","article-title":"DJ-1-binding compound B enhances Nrf2 activity through the PI3-kinase-Akt pathway by DJ-1-dependent inactivation of PTEN","volume":"1729","author":"Niki","year":"2020","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3370","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2009.10.009","article-title":"Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells","volume":"32","author":"Nitta","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3375","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b00101","article-title":"Proteasome activation as a new therapeutic approach to target proteotoxic disorders","author":"Njomen","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7607","key":"10.1016\/j.pharmthera.2020.107579_bb3380","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3385","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: Structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Seminars in Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3390","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Human Mutation"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"O'Connor","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb3400","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3405","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5468","key":"10.1016\/j.pharmthera.2020.107579_bb3410","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3415","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2015.12.041","article-title":"Macular versus retinal nerve fiber layer parameters for diagnosing manifest glaucoma: A systematic review of diagnostic accuracy studies","volume":"123","author":"Oddone","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3420","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3425","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/OTT.S49187","article-title":"An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"Oncotargets and Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3430","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1006\/bbrc.1999.0635","article-title":"Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells","volume":"258","author":"Ogiso","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"23\u201324","key":"10.1016\/j.pharmthera.2020.107579_bb3435","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1016\/j.bmc.2018.11.001","article-title":"Synthesis and biological evaluation of thielocin B1 analogues as protein-protein interaction inhibitors of PAC3 homodimer","volume":"26","author":"Ohsawa","year":"2018","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb3440","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2443.2010.01426.x","article-title":"p62\/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria","volume":"15","author":"Okatsu","year":"2010","journal-title":"Genes to Cells"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3445","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jjco\/hyy108","article-title":"Proteasome inhibitors for multiple myeloma","volume":"48","author":"Okazuka","year":"2018","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3450","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1515\/hsz-2018-0458","article-title":"Posttranslational modifications and proteinopathies: How guardians of the proteome are defeated","volume":"400","author":"Olzscha","year":"2019","journal-title":"Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3455","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cell.2010.11.050","article-title":"Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions","volume":"144","author":"Olzscha","year":"2011","journal-title":"Cell"},{"issue":"43","key":"10.1016\/j.pharmthera.2020.107579_bb3460","doi-asserted-by":"crossref","first-page":"40302","DOI":"10.1074\/jbc.M206428200","article-title":"Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2)","volume":"277","author":"Opazo","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3465","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2141.2009.07998.x","article-title":"Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma","volume":"148","author":"Orciuolo","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"50","key":"10.1016\/j.pharmthera.2020.107579_bb3470","doi-asserted-by":"crossref","first-page":"15318","DOI":"10.1021\/bi0116240","article-title":"Selective activation of the 20 S proteasome (multicatalytic proteinase complex) by histone h3","volume":"40","author":"Orlowski","year":"2001","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107579_bb3475","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1021\/bi00238a025","article-title":"Regulation of the peptidylglutamyl-peptide hydrolyzing activity of the pituitary multicatalytic proteinase complex","volume":"30","author":"Orlowski","year":"1991","journal-title":"Biochemistry"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb3480","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.30026","article-title":"Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"122","author":"Orlowski","year":"2016","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb3485","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb3490","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3495","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0006-291X(81)91823-4","article-title":"A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides","volume":"101","author":"Orlowski","year":"1981","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3500","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1242\/dmm.013391","article-title":"Aneuploidy: Implications for protein homeostasis and disease","volume":"7","author":"Oromendia","year":"2014","journal-title":"Disease Models & Mechanisms"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb3505","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00018-007-7222-8","article-title":"Is the ubiquitin-proteasome system impaired in Huntington's disease?","volume":"64","author":"Ortega","year":"2007","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3510","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fnmol.2014.00077","article-title":"Ubiquitin-proteasome system involvement in Huntington's disease","volume":"7","author":"Ortega","year":"2014","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3515","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25061439","article-title":"New peptide-based pharmacophore activates 20S proteasome","volume":"25","author":"Osmulski","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3520","doi-asserted-by":"crossref","DOI":"10.1159\/000350496","article-title":"Citicoline oral solution in glaucoma: is there a role in slowing disease progression?","author":"Ottobelli","year":"2013","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3525","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1038\/ncomms4396","article-title":"Quantitative live-cell imaging reveals spatio-temporal dynamics and cytoplasmic assembly of the 26S proteasome","volume":"5","author":"Pack","year":"2014","journal-title":"Nature Communications"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb3530","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.celrep.2016.02.068","article-title":"Assembly of an evolutionarily conserved alternative proteasome isoform in human cells","volume":"14","author":"Padmanabhan","year":"2016","journal-title":"Cell Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb3535","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3540","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"34","key":"10.1016\/j.pharmthera.2020.107579_bb3545","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb3550","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3555","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb3560","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/MCB.01210-10","article-title":"Not4 E3 ligase contributes to proteasome assembly and functional integrity in part through Ecm29","volume":"31","author":"Panasenko","year":"2011","journal-title":"Molecular and Cellular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3565","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ajpath.2010.11.010","article-title":"Proteasome inhibitors induce p53-independent apoptosis in human cancer cells","volume":"178","author":"Pandit","year":"2011","journal-title":"The American Journal of Pathology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3570","first-page":"809","article-title":"Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells","volume":"19","author":"Pang","year":"2007","journal-title":"International Journal of Molecular Medicine"},{"issue":"7701","key":"10.1016\/j.pharmthera.2020.107579_bb3575","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-018-0026-1","article-title":"Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity","volume":"556","author":"Pao","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3580","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3585","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1200\/JCO.2013.52.3522","article-title":"Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"33","author":"Papadopoulos","year":"2015","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb3590","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/ars.2015.6494","article-title":"18\u03b1-Glycyrrhetinic acid proteasome activator decelerates aging and Alzheimer's disease progression in Caenorhabditis elegans and neuronal cultures","volume":"25","author":"Papaevgeniou","year":"2016","journal-title":"Antioxidants and Redox Signaling"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb3595","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3600","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0079-6123(08)01137-0","article-title":"Evidence of the neuroprotective role of citicoline in glaucoma patients","volume":"173","author":"Parisi","year":"2008","journal-title":"Progress in Brain Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3605","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s12325-019-0897-z","article-title":"Enhancement of retinal function and of neural conduction along the visual pathway induced by treatment with citicoline eye drops in liposomal formulation in open angle glaucoma: A pilot electrofunctional study","volume":"36","author":"Parisi","year":"2019","journal-title":"Advances in Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3610","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2174\/1570159X15666170703111729","article-title":"Citicoline and retinal ganglion cells: Effects on morphology and function","volume":"16","author":"Parisi","year":"2018","journal-title":"Current Neuropharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb3615","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/S1388-2457(01)00620-4","article-title":"Morphological and functional retinal impairment in Alzheimer's disease patients","volume":"112","author":"Parisi","year":"2001","journal-title":"Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3620","doi-asserted-by":"crossref","unstructured":"Parisi V et al. (2015) Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. PMDI 26004075","DOI":"10.1007\/s00417-015-3044-9"},{"issue":"42","key":"10.1016\/j.pharmthera.2020.107579_bb3625","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.1074\/jbc.M111.285924","article-title":"Structural defects in the regulatory particle-core particle interface of the proteasome induce a novel proteasome stress response","volume":"286","author":"Park","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"7450","key":"10.1016\/j.pharmthera.2020.107579_bb3630","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature12123","article-title":"Reconfiguration of the proteasome during chaperone-mediated assembly","volume":"497","author":"Park","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Translational Research: The Journal of Laboratory and Clinical Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb3640","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3645","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000350412","article-title":"Functional retinal impairment in type 1 diabetic patients without any signs of retinopathy","volume":"50","author":"Parravano","year":"2013","journal-title":"Ophthalmic Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3650","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1073\/pnas.1117648108","article-title":"The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together","volume":"109","author":"Pathare","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3655","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1400546111","article-title":"Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11","author":"Pathare","year":"2014","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb3660","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3665","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","article-title":"Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites","volume":"33","author":"Pekol","year":"2005","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"6418","key":"10.1016\/j.pharmthera.2020.107579_bb3670","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav0725","article-title":"Substrate-engaged 26S proteasome structures reveal mechanisms for ATP-hydrolysis-driven translocation","volume":"362","author":"de la Pe\u00f1a","year":"2018","journal-title":"Science (New York, N.Y.)"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb3675","doi-asserted-by":"crossref","first-page":"910","DOI":"10.5414\/CP203109","article-title":"Bortezomib-induced syndrome of inappropriate antidiuresis in a patient with multiple myeloma: A case report and literature review","volume":"55","author":"Peng","year":"2017","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3680","doi-asserted-by":"crossref","DOI":"10.3390\/md17060329","article-title":"Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets","volume":"17","author":"Pereira","year":"2019","journal-title":"Marine Drugs"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3685","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-\u03baB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nature Reviews. Cancer"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3690","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1073\/pnas.84.9.3033","article-title":"Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains","volume":"84","author":"Perry","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3695","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","article-title":"CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation","volume":"13","author":"Petrucelli","year":"2004","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3700","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"Journal of Immunology (Baltimore, MD: 1950)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3705","doi-asserted-by":"crossref","first-page":"9763507","DOI":"10.1155\/2018\/9763507","article-title":"Association between early neuroretinal dysfunction and peripheral motor unit loss in patients with type 1 diabetes mellitus","volume":"2018","author":"Picconi","year":"2018","journal-title":"Journal of Diabetes Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3710","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12020-019-02017-5","article-title":"Activation of retinal M\u00fcller cells in response to glucose variability","volume":"65","author":"Picconi","year":"2019","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3715","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00592-017-0971-4","article-title":"Retinal neurodegeneration in patients with type 1 diabetes mellitus: The role of glycemic variability","volume":"54","author":"Picconi","year":"2017","journal-title":"Acta Diabetologica"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3720","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","article-title":"Mechanisms underlying ubiquitination","volume":"70","author":"Pickart","year":"2001","journal-title":"Annual Review of Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3725","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.abb.2012.04.018","article-title":"Differential roles of proteasome and immunoproteasome regulators Pa28\u03b1\u03b2, Pa28\u03b3 and Pa200 in the degradation of oxidized proteins","volume":"523","author":"Pickering","year":"2012","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3730","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1042\/BJ20100878","article-title":"The immunoproteasome, the 20S proteasome, and the PA28\u03b1\u03b2 proteasome regulator are oxidative-stress-adaptive proteolytic complexes","volume":"432","author":"Pickering","year":"2010","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3735","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000492886","article-title":"Oxidative stress is the principal contributor to inflammasome activation in retinal pigment epithelium cells with defunct proteasomes and autophagy","volume":"49","author":"Piippo","year":"2018","journal-title":"Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb3740","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nm1095-1046","article-title":"Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis","volume":"1","author":"Pisha","year":"1995","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3745","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3750","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","article-title":"Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration","volume":"98","author":"Podar","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3755","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajhg.2018.04.010","article-title":"Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome","volume":"102","author":"Poli","year":"2018","journal-title":"American Journal of Human Genetics"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb3760","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1016\/j.jmb.2017.09.015","article-title":"Meddling with fate: The proteasomal deubiquitinating enzymes","volume":"429","author":"de Poot","year":"2017","journal-title":"Journal of Molecular Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3765","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Current Cancer Drug Targets"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3770","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/md8040835","article-title":"Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides","volume":"8","author":"Potts","year":"2010","journal-title":"Marine Drugs"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3775","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1146\/annurev.biochem.052308.114844","article-title":"Biological and chemical approaches to diseases of proteostasis deficiency","volume":"78","author":"Powers","year":"2009","journal-title":"Annual Review of Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3780","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.emboj.7601465","article-title":"The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity","volume":"26","author":"Poyurovsky","year":"2007","journal-title":"The EMBO Journal"},{"issue":"5447","key":"10.1016\/j.pharmthera.2020.107579_bb3785","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1126\/science.286.5447.2162","article-title":"Impaired immunoproteasome assembly and immune responses in PA28\u2212\/\u2212 mice","volume":"286","author":"Preckel","year":"1999","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3790","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3795","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cell.2013.04.032","article-title":"Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis","volume":"153","author":"Qian","year":"2013","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb3800","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Research"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107579_bb3805","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1038\/sj.emboj.7601450","article-title":"hRpn13\/ADRM1\/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37","volume":"25","author":"Qiu","year":"2006","journal-title":"The EMBO Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3810","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092845","article-title":"Cellular processing of myocilin","volume":"9","author":"Qiu","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3815","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00280-017-3287-8","article-title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): An open-label, single-arm, phase I study","volume":"79","author":"Quach","year":"2017","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3820","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12325-016-0333-6","article-title":"Quality of life in glaucoma: A review of the literature","volume":"33","author":"Quaranta","year":"2016","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3825","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.1994.tb05044.x","article-title":"Over-expression of the MDM2 gene is found in some cases of haematological malignancies","volume":"88","author":"Quesnel","year":"1994","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-11-76","article-title":"Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor","volume":"11","author":"Qureshi","year":"2012","journal-title":"Lipids in Health and Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3835","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-018-0697-5","article-title":"Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs","volume":"17","author":"Qureshi","year":"2018","journal-title":"Lipids in Health and Disease"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb3840","doi-asserted-by":"crossref","first-page":"7880","DOI":"10.1128\/JVI.00486-10","article-title":"The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice","volume":"84","author":"Raaben","year":"2010","journal-title":"Journal of Virology"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb3845","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.1128\/JVI.00485-10","article-title":"The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle","volume":"84","author":"Raaben","year":"2010","journal-title":"Journal of Virology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb3850","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nsmb962","article-title":"Diverse polyubiquitin interaction properties of ubiquitin-associated domains","volume":"12","author":"Raasi","year":"2005","journal-title":"Nature Structural & Molecular Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3855","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molcel.2008.03.004","article-title":"Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases","volume":"30","author":"Rabl","year":"2008","journal-title":"Molecular Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb3860","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1158\/1535-7163.MCT-11-0555","article-title":"The ubiquitin-proteasome system meets angiogenesis","volume":"11","author":"Rahimi","year":"2012","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3865","doi-asserted-by":"crossref","first-page":"23116","DOI":"10.1038\/srep23116","article-title":"Functionally different \u03b1-synuclein inclusions yield insight into Parkinson's disease pathology","volume":"6","author":"Raiss","year":"2016","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3870","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3875","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nsmb.3389","article-title":"A mammalian nervous system-specific plasma membrane proteasome complex that modulates neuronal function","volume":"24","author":"Ramachandran","year":"2017","journal-title":"Nature Structural & Molecular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3880","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.str.2008.07.001","article-title":"PACemakers of proteasome core particle assembly","volume":"16","author":"Ramos","year":"2008","journal-title":"Structure (London, England: 1993)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3885","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4161\/pri.27776","article-title":"The aggregation of mutant p53 produces prion-like properties in cancer","volume":"8","author":"Rangel","year":"2014","journal-title":"Prion"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb3890","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1074\/jbc.RA118.004671","article-title":"p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells","volume":"294","author":"Rangel","year":"2019","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3895","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1747-1028-7-26","article-title":"Therapeutic targeting of cancer cell cycle using proteasome inhibitors","volume":"7","author":"Rastogi","year":"2012","journal-title":"Cell Division"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3900","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.chembiol.2014.02.006","article-title":"PA28\u03b1\u03b2 reduces size and increases hydrophilicity of 20S immunoproteasome peptide products","volume":"21","author":"Raule","year":"2014","journal-title":"Chemistry & Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb3905","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.bbamcr.2014.05.005","article-title":"Enhanced rate of degradation of basic proteins by 26S immunoproteasomes","volume":"1843","author":"Raule","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3910","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mam.2016.05.001","article-title":"Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways","volume":"50","author":"Raynes","year":"2016","journal-title":"Molecular Aspects of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb3915","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","article-title":"The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression","volume":"2","author":"Read","year":"1995","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3920","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tcb.2004.11.003","article-title":"Mobilizing the proteolytic machine: Cell biological roles of proteasome activators and inhibitors","volume":"15","author":"Rechsteiner","year":"2005","journal-title":"Trends in Cell Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3925","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00394-015-0894-1","article-title":"Resveratrol reduces amyloid-beta (A\u03b2\u2081\u208b\u2084\u2082)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans","volume":"55","author":"Regitz","year":"2016","journal-title":"European Journal of Nutrition"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2020.107579_bb3930","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1042\/bj3350637","article-title":"Comparative resistance of the 20S and 26S proteasome to oxidative stress","volume":"335","author":"Reinheckel","year":"1998","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb3935","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/abbi.2000.1717","article-title":"Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress","volume":"377","author":"Reinheckel","year":"2000","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3940","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.exer.2008.08.011","article-title":"Glaucoma-associated myocilin: A better understanding but much more to learn","volume":"88","author":"Resch","year":"2009","journal-title":"Experimental Eye Research"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb3945","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3950","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb3955","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb3960","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb3965","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb3970","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood.V122.21.535.535","article-title":"Twice-weekly Oral MLN9708 (ixazomib citrate), An investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (Dex) in patients (Pts) with newly diagnosed multiple myeloma (MM): Final phase 1 results and phase 2 data","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb3975","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.15394","article-title":"Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma","volume":"182","author":"Richardson","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb3980","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annual Review of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb3985","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb3990","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107579_bb3995","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4000","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb4005","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb4010","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb4015","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/10428194.2017.1321750","article-title":"Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study","volume":"60","author":"Robak","year":"2019","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4025","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"The Lancet. Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4035","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2020.01.002","article-title":"Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management","author":"Roberti","year":"2020","journal-title":"Survey of Ophthalmology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4040","doi-asserted-by":"crossref","first-page":"28401","DOI":"10.3390\/ijms161226099","article-title":"Cytidine 5\u2032-diphosphocholine (citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives","volume":"16","author":"Roberti","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Roccaro","year":"2006","journal-title":"Cancer Research"},{"issue":"7248","key":"10.1016\/j.pharmthera.2020.107579_bb4050","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nature08063","article-title":"Chaperone-mediated pathway of proteasome regulatory particle assembly","volume":"459","author":"Roelofs","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","article-title":"Positioning of proteasome inhibitors in therapy of solid malignancies","volume":"81","author":"Roeten","year":"2018","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(01)00847-3","article-title":"Oncogenic functions of tumour suppressor p21(Waf1\/Cip1\/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts","volume":"179","author":"Roninson","year":"2002","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2018.10.002","article-title":"Impaired visual search in children with Rett syndrome","volume":"92","author":"Rose","year":"2019","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jnr.22178","article-title":"Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function","volume":"88","author":"Rosen","year":"2010","journal-title":"Journal of Neuroscience Research"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107579_bb4075","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","article-title":"PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma","volume":"88","author":"Rosenberg","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1432-1033.1989.tb15138.x","article-title":"Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent","volume":"185","author":"Rosenberg-Hasson","year":"1989","journal-title":"European Journal of Biochemistry"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb4085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb4090","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"7615","key":"10.1016\/j.pharmthera.2020.107579_bb4095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature18943","article-title":"An evolutionarily conserved pathway controls proteasome homeostasis","volume":"536","author":"Rousseau","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb4105","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4110","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","author":"Rowinsky","year":"2020","journal-title":"Investigational New Drugs"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4115","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb4120","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1093\/emboj\/17.17.4909","article-title":"Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome","volume":"17","author":"Rubin","year":"1998","journal-title":"The EMBO Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/bj2960093","article-title":"Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase","volume":"296","author":"Ruiz de Mena","year":"1993","journal-title":"Biochemical Journal"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb4130","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","article-title":"The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia","volume":"5","author":"Ruiz","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"issue":"7317","key":"10.1016\/j.pharmthera.2020.107579_bb4135","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature09444","article-title":"The proteasome antechamber maintains substrates in an unfolded state","volume":"467","author":"Ruschak","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4140","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2010.02.002","article-title":"Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening","volume":"37","author":"Sadre-Bazzaz","year":"2010","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fphar.2018.00481","article-title":"Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR)","volume":"9","author":"Saeed","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4150","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0006-291X(02)00340-6","article-title":"Ubiquitin-like proteins and Rpn10 play cooperative roles in ubiquitin-dependent proteolysis","volume":"293","author":"Saeki","year":"2002","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-61779-474-2_22","article-title":"Assembly and function of the proteasome","volume":"832","author":"Saeki","year":"2012","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4160","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2009.05.005","article-title":"Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle","volume":"137","author":"Saeki","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087513","article-title":"Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6\/2 mouse model of Huntington's disease","volume":"9","author":"Safren","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4170","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1083\/jcb.201612111","article-title":"Shaping proteostasis at the cellular, tissue, and organismal level","volume":"216","author":"Sala","year":"2017","journal-title":"The Journal of Cell Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4175","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CAD.0000000000000862","article-title":"Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System","volume":"31","author":"Sanagawa","year":"2020","journal-title":"Anti-Cancer Drugs"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4190","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.leukres.2012.07.018","article-title":"CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma","volume":"36","author":"Sanchez","year":"2012","journal-title":"Leukemia Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Sanchez","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2017.03.002","article-title":"Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and\/or dexamethasone (Dex)","volume":"57","author":"Sanchez","year":"2017","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1959","article-title":"Success in translational research: Lessons from the development of bortezomib","volume":"5","author":"S\u00e1nchez-Serrano","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4210","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb4215","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4220","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3324\/haematol.2017.185991","article-title":"A phase I\/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma","volume":"103","author":"San-Miguel","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4225","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"The Lancet. Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4230","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"The Lancet. Haematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4235","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1039\/C5SC03312H","article-title":"Cationic porphyrins are tunable gatekeepers of the 20S proteasome","volume":"7","author":"Santoro","year":"2016","journal-title":"Chemical Science"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb4240","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1021\/ja300781u","article-title":"Cationic porphyrins are reversible proteasome inhibitors","volume":"134","author":"Santoro","year":"2012","journal-title":"Journal of the American Chemical Society"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep33444","article-title":"Copper(II) ions affect the gating dynamics of the 20S proteasome: A molecular and in cell study","volume":"6","author":"Santoro","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4250","doi-asserted-by":"crossref","first-page":"16150","DOI":"10.1038\/s41598-019-52534-6","article-title":"Parkin truncating variants result in a loss-of-function phenotype","volume":"9","author":"Santos","year":"2019","journal-title":"Scientific Reports"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb4255","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/MCB.00216-10","article-title":"PAC1 gene knockout reveals an essential role of chaperone-mediated 20S proteasome biogenesis and latent 20S proteasomes in cellular homeostasis","volume":"30","author":"Sasaki","year":"2010","journal-title":"Molecular and Cellular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms8484","article-title":"Thymoproteasomes produce unique peptide motifs for positive selection of CD8 + T cells","volume":"6","author":"Sasaki","year":"2015","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092231","article-title":"Molecular and structural basis of the proteasome \u03b1 subunit assembly mechanism mediated by the proteasome-assembling chaperone PAC3-PAC4 heterodimer","volume":"20","author":"Satoh","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"49","key":"10.1016\/j.pharmthera.2020.107579_bb4270","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1039\/c3cc42069h","article-title":"A ratiometric naphthalimide sensor for live cell imaging of copper(i)","volume":"49","author":"Satriano","year":"2013","journal-title":"Chemical Communications"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb4275","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00221-017-4962-z","article-title":"Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse","volume":"235","author":"Savolainen","year":"2017","journal-title":"Experimental Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4280","doi-asserted-by":"crossref","first-page":"113977","DOI":"10.1016\/j.bcp.2020.113977","article-title":"Structural and functional evidence for citicoline binding and modulation of 20S proteasome activity: Novel insights into its pro-proteostatic effect","volume":"177","author":"Sbardella","year":"2020","journal-title":"Biochemical Pharmacology"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb4285","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1007\/s00018-018-2807-y","article-title":"The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S","volume":"75","author":"Sbardella","year":"2018","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb4290","doi-asserted-by":"crossref","first-page":"165793","DOI":"10.1016\/j.bbadis.2020.165793","article-title":"Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations","volume":"1866","author":"Sbardella","year":"2020","journal-title":"Biochimica Et Biophysica Acta. Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2020.107579_bb9290","doi-asserted-by":"crossref","unstructured":"Sbardella D., Tundo G.R., Campagnolo L., Valacchi G., Orlandi A., Curatolo P., Borsellino G., D'Esposito M., Ciaccio C., Di Cesare S., Di Pierro D., Galasso C., Santarone M.E., Hayek J., Coletta M., (2017). Stefano Marini Retention of Mitochondria in Mature Human Red Blood Cells as the Result of Autophagy Impairment in Rett Syndrome Sci Rep. 7(1):12297. http:\/\/doi.org\/10.1038\/s41598-017-12069-0.","DOI":"10.1038\/s41598-017-12069-0"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb4295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132455","article-title":"Proteasome activity is affected by fluctuations in insulin-degrading enzyme distribution","volume":"10","author":"Sbardella","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4300","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trsl.2017.11.004","article-title":"Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline","volume":"193","author":"Schaler","year":"2018","journal-title":"Translational Research: The Journal of Laboratory and Clinical Medicine"},{"issue":"6509","key":"10.1016\/j.pharmthera.2020.107579_bb4310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/373081a0","article-title":"Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade","volume":"373","author":"Scheffner","year":"1995","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4315","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","article-title":"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo","volume":"90","author":"Scherzinger","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4320","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/837015","article-title":"The ubiquitin-proteasome system in Huntington's disease: Are proteasomes impaired, initiators of disease, or coming to the rescue?","volume":"2012","author":"Schipper-Krom","year":"2012","journal-title":"Biochemistry Research International"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","article-title":"Regulation of proteasome activity in health and disease","volume":"1843","author":"Schmidt","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107579_bb4330","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1002\/j.1460-2075.1996.tb01081.x","article-title":"Analysis of mammalian 20S proteasome biogenesis: The maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis","volume":"15","author":"Schmidtke","year":"1996","journal-title":"The EMBO Journal"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb4335","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1128\/JVI.01001-12","article-title":"Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain","volume":"86","author":"Schneider","year":"2012","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4340","series-title":"The Dynamic State of Body Constituents","author":"Schoenheimer","year":"1946"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4345","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0021-9258(18)73846-5","article-title":"Studies in protein metabolism vii. The metabolism of tyrosine","volume":"127","author":"Schoenheimer","year":"1939","journal-title":"Journal of Biological Chemistry"},{"issue":"6299","key":"10.1016\/j.pharmthera.2020.107579_bb4350","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aaf8993","article-title":"The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design","volume":"353","author":"Schrader","year":"2016","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126768","article-title":"Immunoproteasome deficiency protects in the retina after optic nerve crush","volume":"10","author":"Schuld","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4360","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0960-7404(00)00012-8","article-title":"The role of NF-kappaB\/IkappaB proteins in cancer: implications for novel treatment strategies","volume":"8","author":"Schwartz","year":"1999","journal-title":"Surgical Oncology"},{"issue":"6590","key":"10.1016\/j.pharmthera.2020.107579_bb4365","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/382468a0","article-title":"Autocatalytic processing of the 20S proteasome","volume":"382","author":"Seemuller","year":"1996","journal-title":"Nature"},{"issue":"5210","key":"10.1016\/j.pharmthera.2020.107579_bb4370","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1126\/science.7725107","article-title":"Proteasome from Thermoplasma acidophilum: A threonine protease","volume":"268","author":"Seem\u00fcller","year":"1995","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4375","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-09-0918","article-title":"Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways","volume":"9","author":"Seki","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"issue":"46","key":"10.1016\/j.pharmthera.2020.107579_bb4380","doi-asserted-by":"crossref","first-page":"11903","DOI":"10.1523\/JNEUROSCI.3020-06.2006","article-title":"Expression of mutated mouse myocilin induces open-angle glaucoma in transgenic mice","volume":"26","author":"Senatorov","year":"2006","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056132","article-title":"Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib","volume":"8","author":"Shabaneh","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molcel.2012.07.011","article-title":"The size of the proteasomal substrate determines whether its degradation will be mediated by mono- or polyubiquitylation","volume":"48","author":"Shabek","year":"2012","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4395","doi-asserted-by":"crossref","first-page":"119521","DOI":"10.1016\/j.ica.2020.119521","article-title":"Transition metal complexes as proteasome inhibitors for cancer treatment","volume":"506","author":"Shagufta","year":"2020","journal-title":"Inorganica Chimica Acta"},{"issue":"34","key":"10.1016\/j.pharmthera.2020.107579_bb4400","doi-asserted-by":"crossref","first-page":"23704","DOI":"10.18632\/oncotarget.25281","article-title":"Efficacy and safety of carfilzomib in relapsed and\/or refractory multiple myeloma: Systematic review and meta-analysis of 14 trials","volume":"9","author":"Shah","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4405","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clml.2019.05.017","article-title":"Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Shah","year":"2019","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107579_bb4410","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/ic060106g","article-title":"Synthesis, structure, and anticancer activity of gallium(III) complexes with asymmetric tridentate ligands: Growth inhibition and apoptosis induction of cisplatin-resistant neuroblastoma cells","volume":"45","author":"Shakya","year":"2006","journal-title":"Inorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4415","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/B978-0-12-397863-9.00010-9","article-title":"Role of the ubiquitin-proteasome in protein quality control and signaling: Implication in the pathogenesis of eye diseases","volume":"109","author":"Shang","year":"2012","journal-title":"Progress in Molecular Biology and Translational Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep12531","article-title":"Insulin-degrading enzyme prevents \u03b1-synuclein fibril formation in a nonproteolytical manner","volume":"5","author":"Sharma","year":"2015","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4425","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2015.09.002","article-title":"Insulin-degrading enzyme is activated by the C-terminus of \u03b1-synuclein","volume":"466","author":"Sharma","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb4430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040267","article-title":"Structural organization of the 19S proteasome lid: Insights from MS of intact complexes","volume":"4","author":"Sharon","year":"2006","journal-title":"PLoS Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4435","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1097-2765(00)80435-9","article-title":"Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination","volume":"5","author":"Sheaff","year":"2000","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4440","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4161\/auto.36098","article-title":"Mutations in the ubiquitin-binding domain of OPTN\/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism","volume":"11","author":"Shen","year":"2015","journal-title":"Autophagy"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4445","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41419-019-2140-x","article-title":"Rod bipolar cells dysfunction occurs before ganglion cells loss in excitotoxin-damaged mouse retina","volume":"10","author":"Shen","year":"2019","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4450","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.biomaterials.2013.09.098","article-title":"The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy","volume":"35","author":"Shen","year":"2014","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4455","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1074\/jbc.M110.175810","article-title":"Processing of optineurin in neuronal cells","volume":"286","author":"Shen","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4460","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"Journal of Advanced Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4465","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/molecules25030671","article-title":"Proteasome inhibitors: Harnessing proteostasis to combat disease","volume":"25","author":"Sherman","year":"2020","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4470","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes & Development"},{"issue":"6275","key":"10.1016\/j.pharmthera.2020.107579_bb4475","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad9421","article-title":"Rpn1 provides adjacent receptor sites for substrate binding and deubiquitination by the proteasome","volume":"351","author":"Shi","year":"2016","journal-title":"Science (New York, N.Y.)"},{"issue":"5528","key":"10.1016\/j.pharmthera.2020.107579_bb4480","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1060627","article-title":"Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease","volume":"293","author":"Shimura","year":"2001","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4485","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1074\/jbc.M305838200","article-title":"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival","volume":"279","author":"Shimura","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4490","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1074\/jbc.M206279200","article-title":"Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome","volume":"278","author":"Shringarpure","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb4495","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/0008-5472.CAN-16-1040","article-title":"Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors","volume":"76","author":"Shukla","year":"2016","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4500","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb4505","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4510","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00018-011-0657-y","article-title":"The role of the proteasome in the generation of MHC class I ligands and immune responses","volume":"68","author":"Sijts","year":"2011","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2020.107579_bb4515","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0161-5890(02)00099-8","article-title":"The role of the proteasome activator PA28 in MHC class I antigen processing","volume":"39","author":"Sijts","year":"2002","journal-title":"Molecular Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4520","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/SHK.0000000000000743","article-title":"Of mice and men: Proteasome's role in LPS-induced inflammation and tolerance","volume":"47","author":"Silswal","year":"2017","journal-title":"Shock (Augusta, GA.)"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4525","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tibs.2014.04.001","article-title":"Prion-like aggregation of mutant p53 in cancer","volume":"39","author":"Silva","year":"2014","journal-title":"Trends in Biochemical Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4530","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cell.2011.05.033","article-title":"Strategies for homeostatic stem cell self-renewal in adult tissues","volume":"145","author":"Simons","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4535","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0021-9258(18)71356-2","article-title":"The release of labeled amino acids from the proteins of rat liver slices","volume":"201","author":"Simpson","year":"1953","journal-title":"The Journal of Biological Chemistry"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb4540","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/S0960-894X(99)00376-5","article-title":"Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology","volume":"9","author":"Sin","year":"1999","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb4545","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2165\/00003088-200443150-00005","article-title":"Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy","volume":"43","author":"Singh","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4550","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","article-title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model","volume":"149","author":"Singh","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4555","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exer.2015.08.020","article-title":"Defects in autophagy caused by glaucoma-associated mutations in optineurin","volume":"144","author":"Sirohi","year":"2016","journal-title":"Experimental Eye Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-49020-4","article-title":"Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome","volume":"9","author":"Sitaraman","year":"2019","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4565","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1164\/rccm.200802-199OC","article-title":"Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome","volume":"179","author":"Sixt","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4570","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/204250","article-title":"Distinct proteasome subpopulations in the alveolar space of patients with the acute respiratory distress syndrome","volume":"2012","author":"Sixt","year":"2012","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4575","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2017.10.034","article-title":"Cancer chemoprevention via activation of proteostatic modules","volume":"413","author":"Sklirou","year":"2018","journal-title":"Cancer Letters"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb4580","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1073\/pnas.1305782110","article-title":"Structure of the 26S proteasome with ATP-\u03b3S bound provides insights into the mechanism of nucleotide-dependent substrate translocation","volume":"110","author":"\u015aled\u017a","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4585","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","article-title":"Regulation of the cdk inhibitor p27 and its deregulation in cancer","volume":"183","author":"Slingerland","year":"2000","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4590","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518794675","article-title":"Could a common mechanism of protein degradation impairment underlie many neurodegenerative diseases?","volume":"12","author":"Smith","year":"2018","journal-title":"Journal of Experimental Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4595","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.06.033","article-title":"Docking of the proteasomal ATPases' C-termini in the 20S proteasomes alpha ring opens the gate for substrate entry","volume":"27","author":"Smith","year":"2007","journal-title":"Molecular Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4600","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.molcel.2005.10.019","article-title":"ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins","volume":"20","author":"Smith","year":"2005","journal-title":"Molecular Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4605","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10637-015-0230-x","article-title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","volume":"33","author":"Smith","year":"2015","journal-title":"Investigational New Drugs"},{"issue":"39","key":"10.1016\/j.pharmthera.2020.107579_bb4610","doi-asserted-by":"crossref","first-page":"16877","DOI":"10.1073\/pnas.0908706106","article-title":"Reversal of long-term dendritic spine alterations in Alzheimer disease models","volume":"106","author":"Smith","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4615","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2019.1596258","article-title":"Ixazomib: An investigational drug for the treatment of lymphoproliferative disorders","volume":"28","author":"Smolewski","year":"2019","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4620","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.arr.2018.11.006","article-title":"Targeting the proteostasis network in Huntington's disease","volume":"49","author":"Soares","year":"2019","journal-title":"Ageing Research Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4625","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10555-017-9705-x","article-title":"Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing","volume":"36","author":"Soave","year":"2017","journal-title":"Cancer Metastasis Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep14909","article-title":"Proteasome activation is mediated via a functional switch of the Rpt6 C-terminal tail following chaperone-dependent assembly","volume":"5","author":"Sokolova","year":"2015","journal-title":"Scientific Reports"},{"issue":"27","key":"10.1016\/j.pharmthera.2020.107579_bb4635","doi-asserted-by":"crossref","first-page":"28807","DOI":"10.1074\/jbc.M403165200","article-title":"Sem1p is a novel subunit of the 26 S proteasome from Saccharomyces cerevisiae","volume":"279","author":"Sone","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4640","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s13238-015-0230-9","article-title":"Parkin promotes proteasomal degradation of p62: Implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease","volume":"7","author":"Song","year":"2016","journal-title":"Protein & Cell"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107579_bb4645","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4650","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ceb.2013.12.006","article-title":"Sorting out the trash: The spatial nature of eukaryotic protein quality control","volume":"26","author":"Sontag","year":"2014","journal-title":"Current Opinion in Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4660","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): Final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4665","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb4670","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.str.2016.07.005","article-title":"The proteasome: More than a means to an end","volume":"24","author":"Spyracopoulos","year":"2016","journal-title":"Structure (London, England: 1993)"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4675","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"VIEWPOINT An english translation of Alzheimer's 1907 Paper, \"ijber eine eigenartige Erlranliung der Hirnrinde\"","volume":"8","author":"Stelzma","year":"1995","journal-title":"Clinical Anatomy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4680","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0609.2010.01450.x","article-title":"BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma","volume":"85","author":"Sterz","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"32","key":"10.1016\/j.pharmthera.2020.107579_bb4685","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4690","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4695","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","article-title":"The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines","volume":"67","author":"Strauss","year":"2007","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4700","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13063-018-2524-8","volume":"19","author":"Striha","year":"2018","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4705","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0006-8993(99)02096-X","article-title":"Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains","volume":"852","author":"Suh","year":"2000","journal-title":"Brain Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4710","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2019.07.051","article-title":"Proteasome inhibition promotes mono-ubiquitination and nuclear translocation of mature (52 kDa) PINK1","volume":"517","author":"Sun","year":"2019","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4715","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4720","first-page":"9","article-title":"Altered functions and interactions of glaucoma-associated mutants of optineurin","author":"Swarup","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4725","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-017-0077-5","article-title":"Protein misfolding in neurodegenerative diseases: Implications and strategies","volume":"6","author":"Sweeney","year":"2017","journal-title":"Translational Neurodegeneration"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb4730","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1158\/0008-5472.CAN-08-3439","article-title":"Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response","volume":"69","author":"Szokalska","year":"2009","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4735","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrn2499","article-title":"Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction","volume":"9","author":"Tai","year":"2008","journal-title":"Nature Reviews. Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4740","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ajpath.2012.06.033","article-title":"The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system","volume":"181","author":"Tai","year":"2012","journal-title":"The American Journal of Pathology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb4745","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/ni.3237","article-title":"TCR affinity for thymoproteasome-dependent positively selecting peptides conditions antigen responsiveness in CD8+ T cells","volume":"16","author":"Takada","year":"2015","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4750","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.isci.2018.11.006","article-title":"USP10 is a driver of ubiquitinated protein aggregation and aggresome formation to inhibit apoptosis","volume":"9","author":"Takahashi","year":"2018","journal-title":"IScience"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4755","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2443.1997.d01-308.x","article-title":"Molecular properties of the proteasome activator PA28 family proteins and \u03b3-interferon regulation","volume":"2","author":"Tanahashi","year":"1997","journal-title":"Genes to Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4760","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: Overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proceedings of the Japan Academy. Series B, Physical and Biological Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4765","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1083\/jcb.96.6.1580","article-title":"ATP serves two distinct roles in protein degradation in reticulocytes, one requiring and one independent of ubiquitin","volume":"96","author":"Tanaka","year":"1983","journal-title":"The Journal of Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4770","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nbd.2011.02.008","article-title":"Gene expression profiling of R6\/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease","volume":"42","author":"Tang","year":"2011","journal-title":"Neurobiology of Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4775","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00401-010-0676-z","article-title":"Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice","volume":"120","author":"Tanji","year":"2010","journal-title":"Acta Neuropathologica"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4780","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00216-004-2697-8","article-title":"Regional distribution of manganese, iron, copper, and zinc in the rat brain during development","volume":"380","author":"Tarohda","year":"2004","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"57","key":"10.1016\/j.pharmthera.2020.107579_bb4785","doi-asserted-by":"crossref","first-page":"97061","DOI":"10.18632\/oncotarget.21221","article-title":"Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer","volume":"8","author":"Taromi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4790","doi-asserted-by":"crossref","first-page":"343560","DOI":"10.1155\/2013\/343560","article-title":"Pathophysiology of diabetic retinopathy","volume":"2013","author":"Tarr","year":"2013","journal-title":"ISRN Ophthalmology"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb4795","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/hmg\/ddr176","article-title":"Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative","volume":"20","author":"Tebbenkamp","year":"2011","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb4800","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3109\/10428194.2015.1106538","article-title":"Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies","volume":"57","author":"Teh","year":"2016","journal-title":"Leukemia & Lymphoma"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4805","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4810","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4815","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41467-018-03509-0","article-title":"A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers","volume":"9","author":"Thibaudeau","year":"2018","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4820","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4825","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-59745-562-6_8","article-title":"Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease","volume":"566","author":"Thomas","year":"2009","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4830","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4835","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/nsmb.2147","article-title":"An asymmetric interface between the regulatory and core particles of the proteasome","volume":"18","author":"Tian","year":"2011","journal-title":"Nature Structural & Molecular Biology"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb4840","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1182\/blood-2012-01-401794","article-title":"Investigational agent MLN9708\/2238 targets tumor-suppressor miR33b in MM cells","volume":"120","author":"Tian","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4845","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601","volume":"172","author":"Till","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4850","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0014-5793(01)03115-5","article-title":"Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome","volume":"509","author":"Tofaris","year":"2001","journal-title":"FEBS Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4855","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ajpath.2011.11.012","article-title":"Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities","volume":"180","author":"Tomaru","year":"2012","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4860","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmech.2017.06.013","article-title":"New comprehensive studies of a gold(III) Dithiocarbamate complex with proven anticancer properties: Aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway","volume":"138","author":"Tomasello","year":"2017","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4865","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2010.02.035","article-title":"Heterohexameric ring arrangement of the eukaryotic proteasomal ATPases: Implications for proteasome structure and assembly","volume":"38","author":"Tomko","year":"2010","journal-title":"Molecular Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4870","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.molcel.2011.11.020","article-title":"Incorporation of the Rpn12 subunit couples completion of proteasome regulatory particle lid assembly to lid-base joining","volume":"44","author":"Tomko","year":"2011","journal-title":"Molecular Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb4875","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molcel.2013.12.009","article-title":"The intrinsically disordered Sem1 protein functions as a molecular tether during proteasome lid biogenesis","volume":"53","author":"Tomko","year":"2014","journal-title":"Molecular Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4880","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cell.2015.09.022","article-title":"A single \u03b1 helix drives extensive remodeling of the proteasome lid and completion of regulatory particle assembly","volume":"163","author":"Tomko","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb4885","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cell.2010.08.038","article-title":"Identification of aneuploidy-tolerating mutations","volume":"143","author":"Torres","year":"2010","journal-title":"Cell"},{"issue":"5840","key":"10.1016\/j.pharmthera.2020.107579_bb4890","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1142210","article-title":"Effects of aneuploidy on cellular physiology and cell division in haploid yeast","volume":"317","author":"Torres","year":"2007","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4895","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1534\/genetics.108.090878","article-title":"Aneuploidy: Cells losing their balance","volume":"179","author":"Torres","year":"2008","journal-title":"Genetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb4900","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/emboj\/20.10.2367","article-title":"A degradation signal located in the C-terminus of p21WAF1\/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome","volume":"20","author":"Touitou","year":"2001","journal-title":"The EMBO Journal"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4905","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/j.1460-2075.1995.tb07287.x","article-title":"Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli","volume":"14","author":"Traenckner","year":"1995","journal-title":"The EMBO Journal"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107579_bb4910","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1002\/j.1460-2075.1994.tb06878.x","article-title":"A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B","volume":"13","author":"Traenckner","year":"1994","journal-title":"The EMBO Journal"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb4915","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1021\/cn500147v","article-title":"Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis","volume":"5","author":"Trippier","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb4920","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1177\/0963689717738785","article-title":"Neuroprotective effects of betulin in pharmacological and transgenic Caenorhabditis elegans models of Parkinson's disease","volume":"26","author":"Tsai","year":"2017","journal-title":"Cell Transplantation"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4925","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.neurobiolaging.2007.04.014","article-title":"Abeta inhibits the proteasome and enhances amyloid and tau accumulation","volume":"29","author":"Tseng","year":"2008","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4930","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev.med.50.1.401","article-title":"The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer","volume":"50","author":"Tsihlias","year":"1999","journal-title":"Annual Review of Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb4935","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.3390\/molecules24142669","article-title":"Porphyrin as diagnostic and therapeutic agent","volume":"24","author":"Tsolekile","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4940","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08467","article-title":"Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome","volume":"4","author":"Tsvetkov","year":"2015","journal-title":"ELife"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4945","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1073\/pnas.1619067114","article-title":"Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers","volume":"114","author":"Tsvetkov","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4950","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059113","article-title":"Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic A\u03b2 peptide aggregates","volume":"8","author":"de Tullio","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb4955","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1074\/jbc.M112.393108","article-title":"Insulin-degrading enzyme (IDE): A novel heat shock-like protein","volume":"288","author":"Tundo","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb4960","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/10409238.2017.1337707","article-title":"Multiple functions of insulin-degrading enzyme: A metabolic crosslight?","volume":"52","author":"Tundo","year":"2017","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb4965","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tibs.2018.08.002","article-title":"Insights into proteasome conformation dynamics and intersubunit communication","volume":"43","author":"Tundo","year":"2018","journal-title":"Trends in Biochemical Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4970","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000500902","article-title":"On the horizon: Targeting next-generation immune checkpoints for cancer treatment","volume":"64","author":"Tundo","year":"2019","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb4975","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/pro.314","article-title":"Amyloidogenic sequences in native protein structures","volume":"19","author":"Tzotzos","year":"2010","journal-title":"Protein Science: A Publication of the Protein Society"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb4980","doi-asserted-by":"crossref","first-page":"12365","DOI":"10.1074\/jbc.M114.558866","article-title":"Characterization of the testis-specific proteasome subunit \u03b14s in mammals","volume":"289","author":"Uechi","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107579_bb4985","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ebiom.2018.05.007","article-title":"Induction of the immunoproteasome subunit Lmp7 links proteostasis and immunity in \u03b1-synuclein aggregation disorders","volume":"31","author":"Ugras","year":"2018","journal-title":"EBioMedicine"},{"issue":"35","key":"10.1016\/j.pharmthera.2020.107579_bb4990","doi-asserted-by":"crossref","first-page":"11805","DOI":"10.1523\/JNEUROSCI.2862-09.2010","article-title":"Parkin directly modulates 26S proteasome activity","volume":"30","author":"Um","year":"2010","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb4995","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1074\/jbc.M504994200","article-title":"Parkin ubiquitinates and promotes the degradation of RanBP2","volume":"281","author":"Um","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5000","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","article-title":"The structure of the mammalian 20S proteasome at 2.75 A resolution","volume":"10","author":"Unno","year":"2002","journal-title":"Structure (London, England: 1993)"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107579_bb5005","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1073\/pnas.1403409111","article-title":"Deep classification of a large cryo-EM dataset defines the conformational landscape of the 26S proteasome","volume":"111","author":"Unverdorben","year":"2014","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb5010","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/emboj\/cdf333","article-title":"PA200, a nuclear proteasome activator involved in DNA repair","volume":"21","author":"Ustrell","year":"2002","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0076-6879(05)98026-9","article-title":"Purification and assay of proteasome activator PA200","volume":"398","author":"Ustrell","year":"2005","journal-title":"Methods in Enzymology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb5020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5025","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2015.00011","article-title":"Distinct effects of ubiquitin overexpression on NMJ structure and motor performance in mice expressing catalytically inactive USP14","volume":"8","author":"Vaden","year":"2015","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1574892811666161102125252","article-title":"Chaperoning the cancer: The proteostatic functions of the heat shock proteins in cancer","volume":"12","author":"Vahid","year":"2017","journal-title":"Recent Patents on Anti-Cancer Drug Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb5035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/cdd.2014.154","article-title":"Proteasome inhibition and oxidative reactions disrupt cellular homeostasis during heme stress","volume":"22","author":"Vallelian","year":"2015","journal-title":"Cell Death and Differentiation"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb5040","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1078-0432.CCR-06-2221","article-title":"Nuclear factor-kappaB in development, prevention, and therapy of cancer","volume":"13","author":"Van Waes","year":"2007","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107579_bb5045","doi-asserted-by":"crossref","first-page":"9493","DOI":"10.1074\/jbc.M117.785287","article-title":"Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism","volume":"292","author":"VanderLinden","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5050","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1110\/ps.052012306","article-title":"The early history of the ubiquitin field","volume":"15","author":"Varshavsky","year":"2006","journal-title":"Protein Science: A Publication of the Protein Society"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5055","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.emboj.7600059","article-title":"Plasticity in eucaryotic 20S proteasome ring assembly revealed by a subunit deletion in yeast","volume":"23","author":"Velichutina","year":"2004","journal-title":"The EMBO Journal"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2020.107579_bb5060","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.clinthera.2009.11.012","article-title":"Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study","volume":"31","author":"Venkatakrishnan","year":"2009","journal-title":"Clinical Therapeutics"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb5065","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"Verbrugge","year":"2012","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5593","key":"10.1016\/j.pharmthera.2020.107579_bb5075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.1075898","article-title":"Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome","volume":"298","author":"Verma","year":"2002","journal-title":"Science (New York, N.Y.)"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221942","article-title":"2D- and 3D-cultures of human trabecular meshwork cells: A preliminary assessment of an in vitro model for glaucoma study","volume":"14","author":"Vernazza","year":"2019","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107579_bb5085","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1042\/BCJ20160809","article-title":"Regulating protein breakdown through proteasome phosphorylation","volume":"474","author":"VerPlank","year":"2017","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4939-8706-1_20","article-title":"Exploring the regulation of proteasome function by subunit phosphorylation","volume":"1844","author":"VerPlank","year":"2018","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb5095","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1073\/pnas.1809254116","article-title":"26S proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation","volume":"116","author":"VerPlank","year":"2019","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jmb.2018.01.004","article-title":"On the trails of the proteasome fold: Structural and functional analysis of the ancestral \u03b2-subunit protein anbu","volume":"430","author":"Vielberg","year":"2018","journal-title":"Journal of Molecular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5105","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1021\/bi00409a025","article-title":"Hemin inhibits ubiquitin-dependent proteolysis in both a higher plant and yeast","volume":"27","author":"Vierstra","year":"1988","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/MN:30:2:201","article-title":"Linkage between the proteasome pathway and neurodegenerative diseases and aging","volume":"30","author":"Vigouroux","year":"2004","journal-title":"Molecular Neurobiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107579_bb5115","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb5120","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1073\/pnas.172504199","article-title":"Amyloid beta -peptide inhibition of the PKA\/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling","volume":"99","author":"Vitolo","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6810","key":"10.1016\/j.pharmthera.2020.107579_bb5125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"6127","key":"10.1016\/j.pharmthera.2020.107579_bb5130","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science (New York, N.Y.)"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb5135","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5140","doi-asserted-by":"crossref","first-page":"14226","DOI":"10.1038\/s41598-017-14618-z","article-title":"Ocular antigen does not cause disease unless presented in the context of inflammation","volume":"7","author":"Voigt","year":"2017","journal-title":"Scientific Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb5145","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5150","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692248","article-title":"Proteasome expression and activity in cancer and cancer stem cells","volume":"39","author":"Voutsadakis","year":"2017","journal-title":"Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pneurobio.2004.10.001","article-title":"Protein quality control in Alzheimer's disease by the ubiquitin proteasome system","volume":"74","author":"de Vrij","year":"2004","journal-title":"Progress in Neurobiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5160","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","article-title":"The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates","volume":"27","author":"Wakabayashi","year":"2007","journal-title":"Neuropathology: Official Journal of the Japanese Society of Neuropathology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5165","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","article-title":"The Lewy body in Parkinson's disease and related neurodegenerative disorders","volume":"47","author":"Wakabayashi","year":"2013","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fonc.2015.00289","article-title":"Mutant p53: One, No One, and One Hundred Thousand","volume":"5","author":"Walerych","year":"2015","journal-title":"Frontiers in Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb5175","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ncb3380","article-title":"Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer","volume":"18","author":"Walerych","year":"2016","journal-title":"Nature Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington\u2010Beddoe","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5185","first-page":"283","article-title":"Cytosine methylation and DNA repair","volume":"301","author":"Walsh","year":"2006","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"39","key":"10.1016\/j.pharmthera.2020.107579_bb5190","doi-asserted-by":"crossref","first-page":"16310","DOI":"10.1074\/jbc.M117.803619","article-title":"The proteasome-interacting Ecm29 protein disassembles the 26S proteasome in response to oxidative stress","volume":"292","author":"Wang","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5195","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/cbdd.12571","article-title":"Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15","volume":"86","author":"Wang","year":"2015","journal-title":"Chemical Biology & Drug Design"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb5200","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/dmd.117.075226","article-title":"In vitro metabolism of oprozomib, an oral proteasome inhibitor: Role of epoxide hydrolases and cytochrome P450s","volume":"45","author":"Wang","year":"2017","journal-title":"Drug Metabolism and Disposition"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb5205","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41422-018-0091-x","article-title":"Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade","volume":"28","author":"Wang","year":"2018","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1743-422X-7-99","article-title":"Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42","volume":"7","author":"Wang","year":"2010","journal-title":"Virology Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5215","first-page":"671","article-title":"Physiological function of myocilin and its role in the pathogenesis of glaucoma in the trabecular meshwork (review)","volume":"43","author":"Wang","year":"2019","journal-title":"International Journal of Molecular Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb5220","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5225","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells","volume":"6","author":"Wang","year":"2016","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb5230","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/mol.113.091322","article-title":"The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death","volume":"85","author":"Wang","year":"2014","journal-title":"Molecular Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5235","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2337\/db09-1420","article-title":"M\u00fcller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage","volume":"59","author":"Wang","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5240","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"151","key":"10.1016\/j.pharmthera.2020.107579_bb5245","doi-asserted-by":"crossref","first-page":"ra88","DOI":"10.1126\/scisignal.2001232","article-title":"Regulation of the 26S proteasome complex during oxidative stress","volume":"3","author":"Wang","year":"2010","journal-title":"Science Signaling"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5250","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb5255","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ceb.2006.10.002","article-title":"Does aneuploidy cause cancer?","volume":"18","author":"Weaver","year":"2006","journal-title":"Current Opinion in Cell Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb5260","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1073\/pnas.1621129114","article-title":"Structural insights into the functional cycle of the ATPase module of the 26S proteasome","volume":"114","author":"Wehmer","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5265","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.biocel.2016.08.008","article-title":"Recent advances in the structural biology of the 26S proteasome","volume":"79","author":"Wehmer","year":"2016","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"483","key":"10.1016\/j.pharmthera.2020.107579_bb5270","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aak9660","article-title":"Regulation of the ubiquitylation and deubiquitylation of CREB-binding protein modulates histone acetylation and lung inflammation","volume":"10","author":"Wei","year":"2017","journal-title":"Science Signaling"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5275","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leukemia & Lymphoma"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb5280","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5285","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","article-title":"Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group","volume":"64","author":"Weisenburger","year":"2000","journal-title":"American Journal of Hematology"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107579_bb5290","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1074\/jbc.M116.717652","article-title":"Inhibition of proteasome activity induces formation of alternative proteasome complexes","volume":"291","author":"Welk","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107579_bb5295","article-title":"How we treat glioblastoma","volume":"4","author":"Weller","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ddtec.2019.02.003","article-title":"Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms","volume":"31","author":"Wertz","year":"2019","journal-title":"Drug Discovery Today: Technologies"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5305","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.205476","article-title":"Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial","author":"Wester","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.pharmthera.2020.107579_bb5310","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drup.2016.07.001","article-title":"Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics","volume":"28","author":"Wijdeven","year":"2016","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2020.107579_bb5315","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1006851428691","article-title":"Synthetic peptide-based activators of the proteasome","volume":"24","author":"Wilk","year":"1997","journal-title":"Molecular Biology Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5320","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.1980.tb07873.x","article-title":"Cation-sensitive neutral endopeptidase: Isolation and specificity of the bovine pituitary enzyme","volume":"35","author":"Wilk","year":"1980","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5325","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1471-4159.1983.tb08056.x","article-title":"Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex","volume":"40","author":"Wilk","year":"1983","journal-title":"Journal of Neurochemistry"},{"issue":"43","key":"10.1016\/j.pharmthera.2020.107579_bb5330","doi-asserted-by":"crossref","first-page":"15280","DOI":"10.1073\/pnas.0504842102","article-title":"The discovery of ubiquitin-dependent proteolysis","volume":"102","author":"Wilkinson","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107579_bb5335","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1158\/0008-5472.CAN-09-0944","article-title":"Aneuploidy \u2013Cancer's fatal flaw?","volume":"69","author":"Williams","year":"2009","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb5340","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13019","article-title":"Cancer and dementia: Two sides of the same coin?","volume":"48","author":"van der Willik","year":"2018","journal-title":"European Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5345","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/ng1006","article-title":"Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease","volume":"32","author":"Wilson","year":"2002","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5350","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1042\/BJ20071338","article-title":"Two different classes of E2 ubiquitin-conjugating enzymes are required for the mono-ubiquitination of proteins and elongation by polyubiquitin chains with a specific topology","volume":"409","author":"Windheim","year":"2008","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-05997-4","article-title":"Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome \u2013 Insights into the enzyme activation mechanism","volume":"7","author":"Witkowska","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmbi.2000.3959","article-title":"Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes","volume":"301","author":"Witt","year":"2000","journal-title":"Journal of Molecular Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0171-9335(98)80083-6","article-title":"Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells","volume":"77","author":"W\u00f3jcik","year":"1998","journal-title":"European Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2017.12.028","article-title":"Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3","volume":"515","author":"Wong","year":"2018","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5375","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.molcel.2017.07.023","article-title":"An AAA motor-driven mechanical switch in Rpn11 controls deubiquitination at the 26S proteasome","volume":"67","author":"Worden","year":"2017","journal-title":"Molecular Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5380","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nsmb.2771","article-title":"Structure of the Rpn11-Rpn8 dimer reveals mechanisms of substrate deubiquitination during proteasomal degradation","volume":"21","author":"Worden","year":"2014","journal-title":"Nature Structural & Molecular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5385","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1471-4159.2009.06037.x","article-title":"Cellular calcium deficiency plays a role in neuronal death caused by proteasome inhibitors","volume":"109","author":"Wu","year":"2009","journal-title":"Journal of Neurochemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb5390","doi-asserted-by":"crossref","first-page":"10749","DOI":"10.3390\/ijms140610749","article-title":"Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of \u03b2-Catenin","volume":"14","author":"Wu","year":"2013","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb5395","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/gtc.12631","article-title":"PAC1-PAC2 proteasome assembly chaperone retains the core \u03b14-\u03b17 assembly intermediates in the cytoplasm","volume":"23","author":"Wu","year":"2018","journal-title":"Genes to Cells: Devoted to Molecular & Cellular Mechanisms"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107579_bb5400","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.2174\/1381612811319180010","article-title":"When ubiquitin meets NF-\u03baB: a trove for anti-cancer drug development","volume":"19","author":"Wu","year":"2013","journal-title":"Current Pharmaceutical Design"},{"issue":"47","key":"10.1016\/j.pharmthera.2020.107579_bb5405","doi-asserted-by":"crossref","first-page":"77622","DOI":"10.18632\/oncotarget.12731","article-title":"Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5410","first-page":"431","article-title":"Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: An observational pilot study","volume":"8","author":"Wunderlich","year":"2002","journal-title":"Molecular Vision"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5415","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13046-019-1227-7","article-title":"Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide","volume":"38","author":"Xia","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107579_bb5420","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1073\/pnas.1222244110","article-title":"Thymoproteasome subunit-\u03b25T generates peptide-MHC complexes specialized for positive selection","volume":"110","author":"Xing","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5425","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10510","article-title":"Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system","volume":"4","author":"Xu","year":"2015","journal-title":"ELife"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107579_bb5430","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/0008-5472.CAN-18-3744","article-title":"Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo","volume":"79","author":"Xue","year":"2019","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5435","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2353\/ajpath.2007.060806","article-title":"Aggregated myocilin induces russell bodies and causes apoptosis","volume":"170","author":"Yam","year":"2007","journal-title":"The American Journal of Pathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5440","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2108\/zsj.15.43","article-title":"Irreversible potent activation and reversible inhibition of trypsin-like activity of 20S proteasome purified from Xenopus oocytes by fatty acid","volume":"15","author":"Yamada","year":"1998","journal-title":"Zoological Science"},{"issue":"42","key":"10.1016\/j.pharmthera.2020.107579_bb5445","doi-asserted-by":"crossref","first-page":"28060","DOI":"10.1074\/jbc.M803077200","article-title":"Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing","volume":"283","author":"Yamano","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"issue":"38","key":"10.1016\/j.pharmthera.2020.107579_bb5450","doi-asserted-by":"crossref","first-page":"13670","DOI":"10.1073\/pnas.0504610102","article-title":"Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase\/Akt signaling","volume":"102","author":"Yang","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb5455","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.xphs.2016.03.015","article-title":"Isostructurality among 5 solvatomorphs of betulin: X-ray structure and characterization","volume":"105","author":"Yang","year":"2016","journal-title":"Journal of Pharmaceutical Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5460","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/138920308784533998","article-title":"Natural compounds with proteasome inhibitory activity for cancer prevention and treatment","volume":"9","author":"Yang","year":"2008","journal-title":"Current Protein & Peptide Science"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb5465","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5470","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/aps.2013.29","article-title":"Crosstalk between the proteasome system and autophagy in the clearance of \u03b1-synuclein","volume":"34","author":"Yang","year":"2013","journal-title":"Acta Pharmacologica Sinica"},{"issue":"6905","key":"10.1016\/j.pharmthera.2020.107579_bb5475","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nature01071","article-title":"A cryptic protease couples deubiquitination and degradation by the proteasome","volume":"419","author":"Yao","year":"2002","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107579_bb5480","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/15548627.2018.1463121","article-title":"Inhibiting autophagy reduces retinal degeneration caused by protein misfolding","volume":"14","author":"Yao","year":"2018","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5485","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ncb1460","article-title":"Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1","volume":"8","author":"Yao","year":"2006","journal-title":"Nature Cell Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5490","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jmb.2019.08.021","article-title":"N-terminal ubiquitination of amyloidogenic proteins triggers removal of their oligomers by the proteasome holoenzyme","volume":"432","author":"Ye","year":"2020","journal-title":"Journal of Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5495","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54846-z","article-title":"A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease","volume":"9","author":"Yeo","year":"2019","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5500","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s13277-012-0386-3","article-title":"The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib","volume":"33","author":"Yerlikaya","year":"2012","journal-title":"Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5505","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12860-015-0060-x","article-title":"Induction of autophagy in rats upon overexpression of wild-type and mutant optineurin gene","volume":"16","author":"Ying","year":"2015","journal-title":"BMC Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5510","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3892\/or.2010.1127","article-title":"Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis","volume":"25","author":"Yoshiba","year":"2011","journal-title":"Oncology Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb5515","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/blood-2006-10-050294","article-title":"p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors","volume":"109","author":"Yu","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5520","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1128\/JVI.79.1.644-648.2005","article-title":"The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry","volume":"79","author":"Yu","year":"2005","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5525","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140173","article-title":"Base-CP proteasome can serve as a platform for stepwise lid formation","volume":"35","author":"Yu","year":"2015","journal-title":"Bioscience Reports"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5530","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01080","article-title":"Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy","volume":"9","author":"Yuan","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb5535","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.jprot.2010.08.008","article-title":"Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders","volume":"73","author":"Zabel","year":"2010","journal-title":"Journal of Proteomics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5540","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbagen.2004.03.016","article-title":"O-GlcNAc a sensor of cellular state: The role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress","volume":"1673","author":"Zachara","year":"2004","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5545","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4161\/cbt.29452","article-title":"Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors","volume":"15","author":"Zang","year":"2014","journal-title":"Cancer Biology & Therapy"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107579_bb5550","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","article-title":"Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy","volume":"18","author":"Zang","year":"2012","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5555","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/JHD-130058","article-title":"The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease","volume":"2","author":"Zeng","year":"2013","journal-title":"Journal of Huntington's Disease"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.02.004","article-title":"Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells","volume":"123","author":"Zhang","year":"2013","journal-title":"Journal of Inorganic Biochemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb5565","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3892\/ijmm.2015.2297","article-title":"Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells","volume":"36","author":"Zhang","year":"2015","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5570","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ica.2017.07.006","article-title":"L-tryptophan Schiff base cadmium(II) complexes as a new class of proteasome inhibitors and apoptosis inducers in human breast cancer cells","volume":"466","author":"Zhang","year":"2017","journal-title":"Inorganica Chimica Acta"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5575","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jcb.22394","article-title":"Inhibition of tumor proteasome activity by gold\u2013dithiocarbamato complexes via both redox-dependent and -independent processes","volume":"109","author":"Zhang","year":"2010","journal-title":"Journal of Cellular Biochemistry"},{"issue":"31","key":"10.1016\/j.pharmthera.2020.107579_bb5580","doi-asserted-by":"crossref","first-page":"22460","DOI":"10.1074\/jbc.M702439200","article-title":"Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6","volume":"282","author":"Zhang","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb5585","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2009.04.021","article-title":"Structural insights into the regulatory particle of the proteasome from Methanocaldococcus jannaschii","volume":"34","author":"Zhang","year":"2009","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb5590","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/1759-7714.12453","article-title":"Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5595","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","author":"Zhang","year":"2020","journal-title":"Science."},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107579_bb5600","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ejic.201600908","article-title":"Redox-active metal complexes for anticancer therapy","volume":"2017","author":"Zhang","year":"2017","journal-title":"European Journal of Inorganic Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5605","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.molcel.2015.05.036","article-title":"MicroRNA-101 suppresses tumor cell proliferation by acting as an endogenous proteasome inhibitor via targeting the proteasome assembly factor POMP","volume":"59","author":"Zhang","year":"2015","journal-title":"Molecular Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107579_bb5610","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(03)00974-7","article-title":"O-GlcNAc modification is an endogenous inhibitor of the proteasome","volume":"115","author":"Zhang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5615","doi-asserted-by":"crossref","first-page":"119248","DOI":"10.1016\/j.biomaterials.2019.119248","article-title":"MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system","volume":"216","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5620","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and Antiphospholipid antibodies in patients with SARS-Cov-2","author":"Zhang","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"45","key":"10.1016\/j.pharmthera.2020.107579_bb5625","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1038\/onc.2016.114","article-title":"A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5630","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/JTO.0000000000000383","article-title":"A phase I\/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321","volume":"10","author":"Zhao","year":"2015","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"52","key":"10.1016\/j.pharmthera.2020.107579_bb5635","doi-asserted-by":"crossref","first-page":"15790","DOI":"10.1073\/pnas.1521919112","article-title":"mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy","volume":"112","author":"Zhao","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107579_bb5640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000838","article-title":"Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice","volume":"6","author":"Zheng","year":"2010","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5645","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2147\/OTT.S130742","article-title":"Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network","volume":"10","author":"Zheng","year":"2017","journal-title":"Oncotargets and Therapy"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5650","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5655","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide Epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107579_bb5660","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1167\/iovs.07-1339","article-title":"Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma","volume":"49","author":"Zhou","year":"2008","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107579_bb5665","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-12-1057","article-title":"Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analog AC17 Causes NF-\u03baB Inhibition and p53 Reactivation in Human Lung Cancer Cells","volume":"12","author":"Zhou","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107579_bb5670","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3892\/or.2015.4169","article-title":"MG132 enhances the radiosensitivity of lung cancer cells in vitro and in vivo","volume":"34","author":"Zhu","year":"2015","journal-title":"Oncology Reports"},{"issue":"41","key":"10.1016\/j.pharmthera.2020.107579_bb5675","doi-asserted-by":"crossref","first-page":"34473","DOI":"10.1074\/jbc.M503736200","article-title":"Control of ASPP2\/53BP2L Protein Levels by Proteasomal Degradation Modulates p53 Apoptotic Function","volume":"280","author":"Zhu","year":"2005","journal-title":"Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107579_bb5680","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/abbs\/gmz093","article-title":"An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro","volume":"51","author":"Zhu","year":"2019","journal-title":"Acta Biochimica et Biophysica Sinica"},{"key":"10.1016\/j.pharmthera.2020.107579_bb5685","article-title":"Nucleotide-Driven Triple-State Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome","author":"Zhu","year":"2017","journal-title":"BioRxiv"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107579_bb5690","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1159\/000443051","article-title":"Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer","volume":"38","author":"Zhu","year":"2016","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"30","key":"10.1016\/j.pharmthera.2020.107579_bb5695","doi-asserted-by":"crossref","first-page":"48725","DOI":"10.18632\/oncotarget.10706","article-title":"USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cells","volume":"8","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107579_bb5700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdermsci.2017.04.009","article-title":"The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin","volume":"88","author":"Zieba","year":"2017","journal-title":"Journal of Dermatological Science"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107579_bb5705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184040","article-title":"Proteasome impairment by \u03b1-synuclein","volume":"12","author":"Zondler","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107579_bb5710","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nsb1194-765","article-title":"Critical elements in proteasome assembly","volume":"1","author":"Zwickl","year":"1994","journal-title":"Nature Structural Biology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:09:42Z","timestamp":1759010982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820301078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":1141,"alternative-id":["S0163725820301078"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107579","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107579"}}